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ABSTRACT 
Different steps forward have been made in the recent years to identify the molecular 
determinants in carcinogenesis and the evidence of a multistep process where cancer cells 
accumulate multiple and consecutive genetic alterations has been formulated. Recently, tumour 
progression has been recognized as the product of a complex crosstalk between tumour cells and 
their surrounding and supporting tissue, named tumour stroma. 
This stroma is known to influence the growth of cancer and it is composed by several types of 
cells, including endothelial cells of blood and lymphatic circulation, stromal fibroblasts and a 
variety of bone marrow-derived cells, such as macrophages, mast cells, neutrophils, lymphocytes 
and mesenchymal stem cells. The supportive microenvironment is generate and modulated by 
cancer cells through the production and activation of stroma growth factors including vascular 
endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and transforming growth 
factor-β (TGF-β). Concomitant with altered growth-factor expressions, induced by their autocrine 
and paracrine effect on the tumour and stromal cells, cancer cells are able to produce proteolytic 
enzymes, such as Matrix metalloproteinases (MMPs), which operate the remodelling of 
extracellular matrix (ECM) and basement membrane, thus activating cell-surface and ECM-bound 
growth factors. All these processes are described to contribute to the extensive crosstalk between 
the microenvironment and the cancer cells. 
Therefore, the microenvironment is implicated in the regulation of cell growth, determining 
angiogenesis, tumour invasion and metastasis, and impacting the outcome. Even if stromal cells 
are not malignant, their role in supporting cancer growth is vital to the survival of the tumour. For 
this purpose, cells of microenvironment have become an attractive target for therapeutic agents.  
The present project has been divided in different tasks to identify the molecular mechanisms 
implicated in cell migration, angiogenesis and tumour growth led by stroma cells and their 
crosstalk with cancer cells in different neoplasia in dog. Canine mammary tumour, cutaneous mast 
cell tumour, lymphoid leukaemia and lymphoma were selected for the study and gene expression 
profiling and proteomic analysis of different growth factors (VEGF-TGF-β-PDGF) and MMPs were 
analyzed in association with their possible prognostic and predictive role and crosstalk.  
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Several important results have obtained highlighting the background of the tumour progression 
and the role of microenvironment in veterinary oncology. Selected results are shown below: 
- MMP-2, MT1-MMP, MMP-9 were significantly involved in canine mammary tumour and a 
significant role of the stromal compartment was described;  
- MMP-9 and VEGF-A were associated with the histological tumour grade in cutaneous mast 
cell tumour; 
- MMP-9, MT1-MMP, TIMP-1 and VEGF were correlated in T-cell lymphoma and in dogs with 
higher stage; 
- A potential role of MT1-MMP and TIMP-2 in the pathogenesis of canine acute 
lymphoblastic leukaemia has been discovered; 
- In chronic lymphocytic leukaemia, residual normal leukocytes have shown a significative 
influence in the expression of MMP-9, MT1-MMP, VEGF and TIMPs; 
- Lymphoma and leukaemia in vitro model exhibited a significative discrepancy that 
enhanced the importance of microenvironment in vivo; 
- PDGF-B mRNA expression was identified in canine T-cell lymphoma and cutaneous 
lymphomas. A functional autocrine and/or paracrine loop of growth stimulation was 
proposed due to the co-expression of PDGFs and PDGFRs at different time point during 
disease.  
Therefore, the obtained results may significantly improve the understanding of cancerogenesis of 
the most frequent tumours in dogs. The summarized data here show a primary role for the 
microenvironment during carcinogenesis. Development of novel cancer therapies that target the 
process of metastasis formation, tumour growth and differentiation, by interfering with the ability 
of cancer cells to transmigrate into blood and lymph vessels and to invade the connective tissue, is 
widely expected in veterinary oncology. Further data are necessary to indicate that the use of 
chemopreventive agents to control the function and behaviour of cells in the microenvironment 
might be an important approach to the overall control of cancer. 
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RIASSUNTO 
Negli ultimi anni nell’ambito dell’oncologia, diversi studi hanno identificato diverse molecole 
target implicate nella cancerogenesi e sono stati evidenziati numerosi processi attraverso cui le 
cellule tumorali sono in grado di accumulare alterazioni genetiche. Recentemente, la progressione 
del tumore è stata riconosciuta come il prodotto di un complesso crosstalk tra le cellule tumorali e 
il tessuto circostante, chiamato stroma tumorale.  
Questo stroma è noto per influenzare la crescita del tumore ed è composto da diverse tipologie 
cellulari, che comprendono cellule endoteliali della circolazione sanguigna e linfatica, fibroblasti 
stromali ed una varietà di cellule derivate dal midollo osseo, come macrofagi, mastociti, neutrofili, 
linfociti e cellule staminali mesenchimali. Ulteriormente, il microambiente di supporto è generato 
e modulato da cellule tumorali attraverso la produzione e attivazione di fattori di crescita prodotti 
dallo stroma stesso, come Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth 
Factor (PDGF) e Transforming Growth Factor-β (TGF). Concomitante all’alterata espressione di 
questi fattori e per il loro effetto autocrino e paracrino sulle cellule tumorali e su quelle stromali, 
le cellule neoplastiche iniziano a produrre enzimi proteolitici, come metalloproteasi di matrice 
(Matrix metalloproteinases - MMPs). Le MMPs operano il rimodellamento della matrice extra 
cellulare e della membrana basale, attivando così fattori di crescita legati alla superficie cellulare e 
alla matrice stessa. Tutti questi processi contribuiscono all’esteso crosstalk tra il microambiente e 
le cellule tumorali.  
Il microambiente quindi è implicato nella regolazione della crescita cellulare, determinando 
neoangiogenesi, invasione, metastasi tumorali e influenzando il risultato della terapia. Anche se le 
cellule stromali non sono considerabili fenotipicamente maligne, il loro ruolo nel sostenere la 
crescita della neoplasia è essenziale per la sopravvivenza del tumore. Con questo presupposto, le 
cellule del microambiente sono diventate un bersaglio attrattivo per diversi agenti terapeutici. 
Il progetto di ricerca è stato suddiviso in diverse fasi per identificare i meccanismi molecolari 
implicati nella migrazione cellulare, nell'angiogenesi e nella crescita neoplastica, da parte di cellule 
stromali e dal loro crosstalk con le cellule tumorali, in diverse neoplasie del cane. Per lo studio 
sono state selezionate le tipologie tumorali più frequenti nel cane: tumore mammario, 
mastocitoma cutaneo, leucemie linfoidi e linfoma, analizzando i profili di espressione genica e 
  Pag. 4 
proteica di diversi fattori di crescita (VEGF-TGF-β-PDGF) e delle MMPs, in associazione al loro 
crosstalk e ad un loro eventuale ruolo prognostico. 
Sono stati ottenuti importanti risultati evidenziando lo scenario della progressione tumorale e il 
ruolo del microambiente in oncologia veterinaria. E’ stato dimostrato che:  
- MMP-2, MT1-MMP, MMP-9 sono significativamente coinvolte nel tumore mammario ed è 
stato descritto un loro ruolo rilevante del compartimento stromale;  
- MMP-9 e VEGF-A sono associati al grado istologico nei mastocitomi cutanei; 
- MMP-9, MT1-MMP, TIMP-1 e VEGF sono correlate nel linfoma T e nei cani con linfoma con 
stadio clinico più alto; 
- MT1-MMP e TIMP-2 hanno un ruolo nella patogenesi nelle leucemie linfoblastiche acute; 
- Nella leucemia linfocitica cronica, i leucociti residui normali mostrano un'influenza 
significativa nell'espressione di MMP-9, MT1-MMP, VEGF e dei TIMPs; 
- Il linfoma e la leucemia nel modello in vitro mostrano una considerevole discrepanza per 
alcune MMPs e VEGF che avvalora l'importanza del microambiente in vivo; 
- L’espressione genica del PDGF-B è significativa nei linfomi T e nei linfomi cutanei. E’ stato 
inoltre proposto un loop funzionale autocrino e/o paracrino di stimolazione della crescita 
della neoplasia, dovuto alla co-espressione dei PDGFs e dei recettori in diversi tempi 
durante la malattia. 
I risultati ottenuti potrebbero migliorare significativamente la comprensione della cancerogenesi 
nei tumori più frequenti nel cane. I dati qui sintetizzati mostrano un ruolo primario del 
microambiente durante la carcinogenesi. Lo sviluppo di nuove terapie antitumorali che colpiscano 
il processo di formazione di metastasi, la crescita e la differenziazione della neoplasia, 
interferendo con la capacità delle cellule tumorali di trasmigrare nel sangue e nei vasi linfatici e di 
invadere il tessuto connettivo, sarà ampiamente perseguito in oncologia veterinaria nel prossimo 
futuro. Sono però necessari ulteriori studi per indicare se l'uso di agenti chemio-preventivi per 
controllare la funzione ed il comportamento delle cellule nel microambiente possa essere un 
importante approccio al controllo complessivo del cancro. 
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ABBREVIATIONS 
ALL = acute lymphoblastic leukaemia 
a.u. = arbitrary unit 
CD = cluster of differentiation 
CGI-119 = canine transmembrane BAX 
inhibitor motif containing 4 
CL = cutaneous lymphoma 
CLL = chronic lymphocytic leukaemia 
CP = crossing point 
DLBCL =diffuse large B-cell lymphoma 
ECM = extra-cellular matrix 
ELISA = enzyme-linked immunosorbent assay 
FNA = fine-needle aspirate 
GOLGA1 = golgin a 1 
GZ = gelatine zymography 
HG = high grade 
HIF = hypoxia-inducible factor 
hNHL = human non-Hodgkin’s lymphoma 
ICC = immunocytochemistry / chemical 
IHC = immunohistochemistry /chemical 
LG = low grade 
LL = lymphoblastic lymphoma 
MCT = mast cell tumour 
MMP = matrix metalloproteinase 
MT-MMP = membrane-type matrix 
metalloproteinase 
MZL = marginal zone lymphoma 
PDGF = platelet-derived growth factor 
PTCL = peripheral T-cell lymphoma 
qRT-PCR = quantitative real time polymerase 
chain reaction 
RECK = reversion- inducing cysteine-rich 
protein with Kazal motifs 
TGF-β = transforming growth factor beta 
TIMP = tissue inhibitor of metalloproteinase 
UPL = universal probe library 
VEGF = vascular endothelial growth factor 
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1. BACKGROUND 
Cancer is one of the causes of disease and mortality worldwide. The past two decades of 
biomedical research have collected an enormous amount of information on the molecular events 
that take place during carcinogenesis and tumour progression. The molecular mechanisms of the 
complex interplay between the tumour cells and the tumour microenvironment have been 
identified playing a pivotal role in this process (Gialeli et al. 2010). A variety of stromal cells in the 
surrounding environment are recruited to tumours, and these not only increase the growth of the 
primary cancer but also facilitate its metastatic dissemination to distant organs (Joyce and Pollard, 
2009) (Fig. 1). Through different mechanisms, the neoplastic cells are able to disseminate by 
lymphatic and blood circulation, and then create metastatic growth in distant organs. To spread 
within the tissues, tumour cells use migration mechanisms that are similar, if not identical, to 
those that occur during physiological processes such as embryonic morphogenesis, would healing 
and immune-cell recruitment (Friedl and Bröcker, 2000). 
Moreover, the cell body is modified in shape and stiffness during the migration to interact with the 
surrounding tissue structures. In vitro and in vivo observations have shown that tumour cells 
infiltrate neighbouring tissues in diverse patterns. They can disseminate in an “individual cell 
migration”, or expand in solid cell strands, sheets, files or clusters (called “collective migration”). 
Leukaemias, lymphomas and solid stromal tumours, such as sarcomas, usually disseminate via 
single cells; whereas epithelial tumours follow collective migration mechanisms. Such differences 
in cellular patterning reflect variations in the molecular repertoire used by a cancer cell to migrate 
(Friedl and Wolf, 2003). 
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Fig. 1. Primary tumour and microenvironment.  Cancer cells in primary tumours have a strict interaction 
with their supportive microenvironment. The environment is composed by some structural cells including 
endothelial cells of blood and lymphatic circulation, stromal fibroblasts and a variety of bone marrow-
derived cells, including macrophages, mast cells, neutrophils, lymphocytes and mesenchymal stem cells. 
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MECHANISMS OF TUMOUR-CELLS INVASION AND MIGRATION 
In vitro studies have led to the original observations that individual tumour cells are motile. These 
cells usually originate from the interstitial stroma or bone marrow. Alternatively, cells that arise 
from a multicellular compartment, such as epithelium, lose their cell contacts, detach and migrate 
as individual cells through the neighbouring connective tissue. Based on cell type, integrin 
involvement, cytoskeletal structure and protease production, single-cell migration can occur in 
different morphological variants (Thiery, 2002). These variants include: 
- Mesenchymal migration.  Mesenchymal movement is predominantly found in cells from 
connective-tissue tumours, such as fibrosarcoma, glioma and in epithelial cancers, the 
latter characterized by a progressive dedifferentiation. The cells following this type of 
cellular patterning have a fibroblast-like spindle-shaped morphology that is dependent on 
integrin-mediated adhesion dynamics and the presence of high traction forces on both cell 
poles.  
- Amoeboid migration. The characteristics of amoeboid movement have been established 
through studies of the single-cell amoeba, Dictyostelium discoideum. Dictyostelium is an 
elliptoid cell that translocates with morphological expansion and contraction; it has an 
extraordinary deformability and relatively low-affinity substrate binding that is integrin 
independent. In higher eukaryotes, signs of amoeboid movement are shown in leukocytes 
and some tumour cells. In lymphocytes and neutrophils, integrin-mediated adhesion is 
useful for cell migration within connective tissue, both in vitro and in vivo. T lymphocytes 
use protease-independent physical mechanisms to overcome matrix barriers. Furthermore 
an amoeboid dissemination characterizes the early detachment and metastatic spread 
from a small primary tumour, such as lymphomas and small-cell lung carcinomas. 
- Chain migration. Chain migration occurs in non-neoplastic neural crest cells, myoblasts, 
breast carcinoma and melanomas. These cells stream one after another in a strand-like 
fashion (Friedl and Wolf, 2003).  
Cancer cells generate a supportive microenvironment by producing stroma-modulating growth 
factors including the vascular endothelial growth factor (VEGF), platelet-derived growth factor 
(PDGF) and transforming growth factor-β (TGF-β). Similar to the processes of wound healing, these 
factors disrupt normal tissue homeostasis and act in a paracrine manner to induce stromal 
reactions such as angiogenesis and inflammatory response. Moreover, they can activate 
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surrounding stromal cells, such as fibroblasts, smooth-muscle cells and adipocytes, leading to the 
secretion of additional growth factors and proteases (Mueller and Fusenig, 2004). Concomitant 
with altered growth-factor expressions, often induced by their autocrine effect on the tumour 
cells, cancer cells initiate to produce proteolytic enzymes, such as Matrix metalloproteinases 
(MMPs) (Stetler-Stevenson and Yu, 2001).  MMPs operate the remodelling of ECM and basement 
membrane, exposing cryptic protein domains and generating specific new molecule fragments 
that can have promigratory as well as pro- and anti-angiogenic functions. Moreover these 
proteases activate cell-surface and ECM-bound growth factors, during ECM degradation, that 
contribute to the extensive crosstalk between the microenvironment and the cancer cells (Mueller 
and Fusenig, 2004) (Fig. 2). 
Therefore progression of tumour is a highly complex process in which several molecular events are 
required for tumour cells to achieve independent growth. Another such event is the enhancement 
of angiogenesis. Angiogenesis is the development of new blood vessels from existing ones, as 
opposed to vasculogenesis, which refers to the de novo formation of blood vessels (Levitovic et al., 
2006). It is necessary for persistent tumour growth, because the sprouting capillaries are conduits 
for gas exchange and nutrient supply. The process of angiogenesis is governed by a strict 
molecular interaction, and its modulation is dependent on angiogenic factors, cytokines, integrins 
and ECM components that surround the involved vessels (Yoon et al., 2003). These interactions 
concern cell-to-cell and cell-to-ECM. The induction and rate of angiogenesis depend on the 
balance of two functionally opposing groups of cytokines called angiogenic and angiostatic (or 
antiangiogenic) factors (“angiogenesis switch model’’) (Levitovic et al., 2006). 
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Fig. 2. Crosstalk between tumour cells and their reactive stromal cells. Tumour cells create a supportive 
microenvironment by secreting growth factors, proteases and their inhibitors, whose imbalance leads to 
the degradation of ECM, resulting in the release of growth factors, bound to the matrix, and of ECM 
molecular fragments. The secretion can act both in autocrine and paracrine manners to the stroma, 
inducing angiogenesis, invasion and proliferation of tumour cells. In addition to recruitment, proliferation 
and activation of stromal inflammatory cells and fibroblasts are activated, secreting further growth factors 
and proteases. This cycle permit to amplify these signals in the cascade that results in the establishment of 
an activated stroma that promotes malignant tumour growth. 
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1.1. MATRIX METALLOPROTEINASES 
 
Matrix metalloproteinases (MMPs) are extracellular matrix remodelling proteinases, which belong 
to a zinc-dependent family of endopeptidases. The MMP family consists of about 24 members that 
are characterized in humans, rodents, and amphibians. Initially, MMPs are classified according to 
their modular domain structure and ECM specificity. In particular, the gelatinases are a subgroup 
within the MMP family and include MMP-2 (gelatinase A or Mr 72,000 type IV collagenase) and 
MMP-9 (gelatinase B or Mr 92,000 type IV collagenase). They have been described in the tumour 
invasion and progression in different human tumours (Egeblad and Werb, 2002). In addition, 
MMPs cleave a lot of substrates, including an array of other proteinases, proteinase inhibitors, 
chemotactic molecules, latent growth factors, growth factor binding proteins, cell surface 
receptors, and cell-cell and cell-matrix adhesion molecules. Thereby they regulate cell behaviour in 
several ways. Therefore, MMPs influence diverse physiologic and pathologic processes. In normal 
physiology, MMPs are involved in embryonic development, wound repair, ovulation, bone 
remodelling, macrophage and neutrophil function. In pathologic conditions, such as rheumatoid 
arthritis, periodontal disease, osteoarthritis, gastric ulcer, arteriosclerosis and then tumour 
invasion, metastasis and angiogenesis in cancer, MMPs operate an excessive and considerable 
degradation of ECM (Yoon et al., 2003) (Fig. 3). 
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Fig. 3. Roles of MMPs in cancer progression. MMPs can modulate several phases of cancer progression, 
including tumour growth and survival, tumour invasion and metastasis at the distant sites and angiogenic 
switch. MMPs exert their proteolytic activity degrading the physical barriers and liberating growth factors, 
thereby facilitating all these phases.  
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1.1.1. REGULATION 
In the neoplastic process, the MMPs are regulated in a paracrine manner by growth factors and 
cytokines secreted both by tumour infiltrating inflammatory cells and tumour or stromal cells. This 
regulation is governed by the continuous crosstalk between tumour cells, stromal cells, and 
inflammatory cells during the invasion process. Most MMPs are secreted as latent precursors 
(zymogens) that are proteolytically activated in the extracellular space, with the exception of 
MMP-11 and Membrane type-1 Matrix Metalloproteinases (MT1-MMP or MMP-14), which are 
activated prior to secretion by Golgi-associated, furin-like proteases (Westermarck and Kahary, 
1999). Endogenous inhibitors tightly control MMP activity. The main inhibitor of MMPs is α2-
macroglobulin, an abundant plasma protein. In a similar way to α2-macroglobulin, 
thrombospondin-2 forms a complex with MMP-2 and facilitates endocytosis and clearance. By 
contrast, thrombospondin-1 binds to pro-MMP-2 and -9 and directly inhibits their activation. 
The most-studied endogenous MMP inhibitors are Tissue Inhibitors of MMPs (TIMPs) -1, -2, -3 and 
-4, which reversibly inhibit MMPs in a 1:1 stoichiometric fashion. They differ in tissue-specific 
expression and ability to inhibit various MMPs (Egeblad and Werb, 2002). Although TIMPs 
inactivate MMPs in vitro, the role of TIMPs in the regulation of MMP activity and cancer 
progression in vivo is unclear. Initial studies have shown decreased expression of TIMPs at the site 
of tumour invasion, but a positive correlation between TIMPs and MMPs expression and poor 
prognosis in malignant tumours has recently been shown. The contradictory roles of TIMPs may 
result from the bimodal function of TIMPs as inhibitors, but also as key players in the activation of 
MMPs. To exert their inhibiting or activating functions, TIMP-1 and TIMP-2 preferentially bind to 
MMP-9 or MMP-2, respectively (Westermarck and Kahary, 1999). 
In addition to TIMPs, the recently characterized RECK (reversion inducing cysteine-rich protein 
with Kazal motifs) protein, a novel plasma-membrane-anchored MMP inhibitor, has been 
described to regulate MMPs activity. RECK controls three members of the MMP family (MMP-2, 
MMP-9 and MT1-MMP) by various mechanisms, inhibiting the secretion or directly the catalytic 
activity (Takahashi et al., 1998). 
MMP gene expression is primarily regulated at the transcriptional level or through the modulation 
of mRNA stability in response to growth factors and cytokines. In fact, the promoter regions of 
inducible MMP genes (MMP-1, MMP-3, MMP-7, MMP-9, MMP-10, MMP-12, MMP-13) show 
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remarkable conservation of regulatory elements, and their expression is induced by growth 
factors, cytokines, and other environmental factors such as contact to ECM (Yoon et al., 2003).  
The pro-MMP-2 can be activated by several mechanisms that are dependent on stimulators and 
cell types. MMP-2 is activated at the cell surface through a unique multistep pathway that involves 
MT1-MMP and TIMP-2: TIMP-2 binds MMP-14 at its amino terminus and pro-MMP-2 at its 
carboxyl terminus, which allows an adjacent, non-inhibited MMP-14 to cleave the bound pro-
MMP-2 (Egeblad and Werb, 2002). 
1.1.2. TUMOUR CELL INVASION, MIGRATION AND PROGRESSION 
High expression levels of certain MMPs were correlated to the tumour invasion capacity in vivo. 
Because of their ECM-degrading activity, MMPs were initially thought to facilitate tumour cell 
metastasis by destroying the basement membrane and other components of ECM. MMPs also 
participate in cell-surface proteolysis, leading to the release of different growth regulators and the 
extracellular domains of proteins from the cell surface (Yoon et al., 2003). Moreover, MMPs act on 
the non-matrix substrates (e. g., chemokines, growth factors, growth factor receptors, adhesion 
molecules, and apoptotic mediators) that operate the rapid and critical cellular responses, which 
are required for tumour growth and progression (Westermarck and Kahary, 1999). 
Furthermore, during invasion, the localization of MMPs to specialized cell surface structures is 
essential for their ability to promote invasion. Specialized cell surface structures utilize 
transmembrane proteinases, including MT1-MMP, as well as secreted and activated MMPs at the 
site, such as MMP-2 and -9, to degrade a variety of ECM macromolecules and facilitate cell 
invasion (Gialeli et al,. 2011). 
1.1.3. IMMUNOLOGIC ESCAPE 
Once the tumour cell has entered the circulation, the immune system is responsible for the 
elimination of the circulating tumour cells. In order to be successful in the establishment of 
metastases, a tumour cell is able to adopt mechanisms of immune escape. MMPs help this process 
stimulating cancer cell-platelet interactions and inhibition of functions, as well as the proliferation 
of immune responsible cells, such as the T cell and natural killer cells (Westermarck and Kahary, 
1999). Moreover MMPs shed interleukin-2 receptor-a by the cell surface of T-lymphocytes, 
thereby suppressing their proliferation; then TGF-b, a significant suppressor of T-lymphocyte 
reaction against cancer cells, is released as a result of MMP activity (Gialeli et al., 2011).  
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1.1.4. ANGIOGENESIS 
MMPs are essential regulators during various phases of the angiogenic process, from the 
deposition and breakdown of the basement membrane of vascular structures, to the endothelial 
cell proliferation and migration (Westermarck and Kahary, 1999). The principal MMPs that 
participate in tumour angiogenesis are mainly MMP-2, -9 and MT1-MMP (Gialeli et al., 2011). In 
particular, besides its proteolytic degradation, MMP-9 can release angiogenic factors bound to 
ECM. While tumour cells may produce latent pro-MMPs, in most tumours, the stromal cells and 
vascular endothelial cells are the major source of pro-MMPs that are activated by distinct MMPs 
or other proteases (Moehler et al., 2003).  
1.1.5. TARGETED THERAPY IN HUMAN  
On the basis of the pivotal roles that MMPs play in several steps of cancer progression, the 
pharmaceutical industry has invested considerable effort over the past 20 years aiming to develop 
safe and effective agents targeting MMPs. In this regard, multiple Matrix Metalloproteinases 
Inhibitors (MMPIs) have been developed, in the attempt to control the synthesis, secretion, 
activation and enzymatic activity of MMPs. Several generations of synthetic MMPIs were tested in 
phase III clinical trials in humans, including peptidomimetics (like Marimastat in breast cancer), 
nonpeptidomimetics inhibitors and tetracycline derivatives (like Metastat, also called COL-3, in 
Kaposi’s sarcoma), which target MMPs in the extracellular space (Gialeli et al., 2011). In addition, 
various natural compounds, like Neovastat in breast and colorectal tumour, have been identified 
as inhibiting MMPs. Other strategies of MMP inhibition in development involve antisense and 
small interfering RNA (siRNA) technology. Antisense strategies are directed selectively against the 
mRNA of a specific MMP, resulting in decrease of RNA translation and downregulation of MMP 
synthesis (Mannello, 2006). However the road to clinical use of MMPIs has not been 
straightforward. Several reasons might explain the unfavourable clinical outcomes in some of the 
MMPI clinical trials in various cancer types. Firstly, adverse effects, including musculoskeletal 
syndrome, have limited the maximum-tolerated dose of the early generation of MMPIs, thereby 
limiting drug efficacy. Secondly, patients recruited in the trials are often at the most advanced and 
metastatic stage of cancer. In addition, the nonspecific nature of the inhibitors has a negative 
impact in their therapeutic efficacy, due to the wide range of MMPs and physiological events 
affected (Roy et al., 2009). Considering all of the above, one of the major challenges for the future 
is the development of inhibitors or monoclonal antibodies that bind to the active site of the 
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enzyme and are specific for certain MMPs, showing little or no cross-reaction with other MMPs 
(Gialeli et al., 2011).  
1.1.6. MMPs IN DOG  
Although evidence for the role of MMPs in tumours of domestic animals is sparse, the central role 
of MMP-2 and MMP-9 has been documented in many pathologies. The sequence homology 
between other species and human MMPs is high; therefore, the use of human standards to 
estimate the location and presence of canine MMPs appears reasonable. There is a 96% to 98% 
sequence homology among rat, mouse, and human MMP-2, whereas there is a 75% to 85% 
sequence homology among rat, mouse, rabbit, human, and bovine MMP-9. An experimental work 
to sequence canine MMP-2 has revealed high sequence homology with human, rat, and mouse 
sequences (Leibman et al., 2000). Furthermore Coughlan et al. (2000) have shown the N-terminal 
amino acid sequence of canine MMP-2 to have 87% homology with the human sequence.  
Increased MMP-2 and MMP-9 levels occur in the synovial fluid in canine rheumatoid arthritis 
(Coughlan et al., 1998) and increased MMP-2 levels in canine osteoarthritis (Coughlan et al., 1995), 
whereas increased pro–MMP-9 levels occur in the myocardium in canine dilated cardiomyopathy 
(Gilbert et al., 1997). Gelatinase activity was significantly elevated in fluids from eyes of dogs with 
keratoconjunctivitis (Arican et al., 1999). More recently MMP-2 and MMP-9 were detected in 
canine osteosarcoma (Loukopoulos et al., 2004), cutaneous mast cell tumours (Leibman et al., 
2000), mammary tumour (Santos et al., 2012), melanoma (Docampo et al., 2011), canine seminal 
plasma (Saengsoi et al., 2011), renal fibrosis (Aresu et al., 2011), myxomatous mitral valve disease 
(Ljungvall et al., 2011), visceral leishmaniasis (Marangoni et al., 2011), meningioma (Mandara et al. 
2009), hemangiosarcomas (Murakami et al., 2009) and lymphoma (Gentilini et al.,2005). 
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1.2. VASCULAR ENDOTHELIAL GROWTH FACTOR 
 
Vascular endothelial growth factor (VEGF) is usually considered an exclusive angiogenic growth 
factor. At least 6 VEGF types have been described: VEGF from A to E and placenta growth factor 
(PlGF). VEGF-A is the most common and most extensively studied isoform. VEGFs are glycosylated 
homodimers with sequence homology (20%) to A and B chains of PDGF and contain a core of 
cysteine residues. Three VEGF receptors—VEGRF-1 (flt-1), VEGFR-2 (KDR/flk-1), and VEGFR-3 (flt-
4)—have been described. They belong to a subfamily of tyrosine kinase receptors within the PDGF 
receptor class and are characterized by 7 extracellular immunoglobulin-like domains. They are 
expressed in endothelial cells from embryogenesis. All VEGF isoforms can bind to VEGFR-1 and 
VEGFR-2. VEGFR-1 and VEGFR-2 are localized to vascular and lymphatic endothelial cells in adult 
tissues. VEGFR-3 is present mostly in the lymphatic endothelium. However, VEGFR-2 is the main 
VEGF receptor in endothelial cells (Halper, 2010). 
1.2.1. REGULATION 
The activity of tyrosine kinase receptors is regulated by the availability of ligands. A particular 
feature of the VEGF-A ligand is the upregulation of its expression levels under hypoxic conditions. 
Hypoxia allows the stabilization of hypoxia-inducible factors (HIFs) that bind to specific promoter 
elements which are present in the promoter region of VEGF-A. Similarly, expression of VEGFR-1 is 
directly regulated by HIFs. VEGFR-2 is also upregulated during hypoxia, but the role of different 
HIFs in its regulation remains to be clarified. VEGFR-3 expression is upregulated in differentiating 
embryonic stem cells that are cultured in a hypoxic atmosphere. After the binding of ligands, the 
VEGFRs are able to form both homodimers and heterodimers. The signal-transduction properties 
of the VEGFR heterodimers compared with homodimers remain to be elucidated. Dimerization of 
receptors is accompanied by activation of the receptor-kinase activity that leads to the 
autophosphorylation of the receptors. Phosphorylated receptors recruit interacting proteins and 
induce the activation of signalling pathways that involve an array of second messengers (Olsson et 
al., 2006). Furthermore several growth factors, including TGF-β, PDGF, and inflammatory 
cytokines, such as IL-6, upregulate VEGF mRNA expression, suggesting that paracrine or autocrine 
release of such factors cooperates with local hypoxia in regulating VEGF release in the 
microenvironment (Ferrara et al., 2003). 
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1.2.2. ANGIOGENESIS AND CANCER 
As mentioned before, angiogenesis plays an important role not only in the tumour growth and its 
blood supply, but also in the tumour metastasis (Fig. 4). Vessels at the tumour periphery modify 
from normal nonproliferating host vessels to tumour vessels generated in response to VEGF, 
without some complicating influences such as tumour secreted proteases, necrosis, hypoxia, and 
increased interstitial pressure, present in the tumour core. During tumourigenesis, neoplastic 
lesions initially undergo an avascular growth phase, followed by a second event, that is 
characterized by the switch from the avascular to vascular phenotype, or “the angiogenic switch”. 
This initiates a cascade of events that results in the expansion of tumour volume and subsequent 
metastasis (Hoeben et al., 2004). Furthermore, according to this accepted hypothesis of 
angiogenic switch, the induction of angiogenesis and subsequent tumour progression is 
dependent on the balance of a multitude of angiogenesis activators or inhibitors in the tumour 
microenvironment. Important activators include VEGF, basic fibroblast growth factor (bFGF), 
PDGF, epidermal growth factor (EGF), granulocyte colony stimulating factor (G-CSF), interleukin-1, 
interleukin-6, interleukin-8, and tumour necrosis factor α (TNFα). Whereas multiple antiangiogenic 
molecules include cytokines such as interferon (IFN)-α and –γ, as well as several peptides 
generated by proteolytic cleavage of the basement membrane and the ECM operated by MMPs. 
Another antiangiogenic pathway is through the release of soluble VEGF receptor-1 (sVEGFR-1) 
(Moehler et al., 2003). Molecular regulations of the angiogenic switch that involve VEGF are 
several. These regulations include: 
- hypoxia-induced upregulation of VEGF; 
- upregulation of VEGF after oncogenic transformation (mutant Ras, c-myc, myb, v-scr, nox-
1); 
- tumour and vascular cell interactions through adhesion molecules (IL-6 and CD40) and 
paracrine stimulatory circuit; 
- remodelling ECM by MMPs and consequently release of angiogenic factors bound to ECM; 
- bone marrow derived endothelial precursor cells; 
- lymphangiogenesis with the expression of VEGF-C (Moehler et al., 2003). 
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Fig. 4: Role of VEGF in tumour angiogenesis. Tumour cells of primary tumour release VEGF that binds to its 
receptors into nearby tissues on the endothelial cells of pre-existing blood vessels, leading to their 
activation. Crosstalk between cancer cells and cells of microenvironment leads to the secretion and 
activation of various proteolytic enzymes, such as MMPs, which degrade the basement membrane and 
ECM, permitting deposition of new basement membrane by endothelial cells. Simultaneously other growth 
factors, such as PDGF, are secreted to attract supporting cells (stromal cells) to stabilize new vessels. 
Integrin molecules, such as αvβ3-integrin, help to pull the sprouting new blood vessels forward. 
 
1.2.3. TARGETED THERAPY IN HUMAN 
Most of the angiogenesis inhibitors that are currently used for the treatment of cancer achieve 
their effects by blocking VEGF. Inhibitors of VEGF not only stop angiogenesis and destroy part of 
the tumour vasculature through apoptosis, but they also normalize tumour vessels. Through rapid 
and robust effects on the tumour vasculature, angiogenesis inhibitors slow the growth of many 
primary tumours and metastasis. Angiogenesis inhibitors have been approved for a wide range of 
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cancer types, including hepatocellular carcinoma and renal cell carcinoma that respond poorly to 
other agents (Sennino  and McDonald, 2012). Bevacizumab, a function-blocking antibody to VEGF, 
is approved for use with chemotherapy to treat metastatic colorectal cancer, metastatic renal cell 
cancer, metastatic breast cancer and metastatic non-small-cell lung cancer; and as a single agent 
for recurrent glioblastoma and advanced ovarian cancer. Multiple other angiogenesis inhibitors 
that are approved for cancer therapy (such as sorafenib, sunitinib, axitinib, pazopanib and 
vandetanib) inhibit VEGF signalling by targeting receptor tyrosine kinases (Bhargava and Robinson, 
2011). Disease progression, as reflected by tumour growth and metastasis during treatment with 
inhibitors of VEGF signalling, is attributed to multiple mechanisms. Among them are compensatory 
actions of angiogenic growth factors that are not blocked by inhibitors of VEGF signalling, blood 
flow alterations owing to tumour-vessel normalization, presence of normal peritumoural blood 
vessels, exaggeration of intratumoural hypoxia, activation of pathways that favour epithelial–
mesenchymal transition (EMT), promotion of tumour invasiveness, suppression of immune 
surveillance, induction of tolerance and activation of cancer stem cells (Sennino and  McDonald, 
2012).  
1.2.4. VEGF IN DOG 
To date, little is known about VEGF and VEGFR expression in normal or pathological canine tissue. 
Scheidegger and colleagues (1999) demonstrated that canine and human VEGF are structurally 
almost identical, with the same biological and cell-binding properties, and that the canine VEGF 
receptors closely resemble their human counterparts. VEGF expression levels in dogs were 
investigated in mammary tumour (Santos et al., 2010), mast cell tumour (Rebuzzi et al., 2007), 
lymphoma (Zizzo et al., 2010), soft tissue sarcoma (Fernandes de Queiroz et al., 2012), congenital 
portosystemic shunt (Tivers et al., 2012), canine vascular tumour (Yonemaru et al., 2006), 
cutaneous fibrosarcoma (Al-Dissi et al., 2009), epithelial nasal tumour (Shiomitsu et al., 2009), 
osteosarcoma (Thamm et al., 2008), oral malignant melanoma (Taylor et al., 2007), cutaneous 
squamous cell carcinoma, trichoepithelioma (Al-Dissi et al., 2007) and primary intracranial 
neoplasms (Rossmeisl et al., 2007). 
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1.3. TRANSFORMING GROWTH FACTOR BETA 
 
The transforming growth factor-β (TGF-β) superfamily of cytokines, which consists of TGFβs, 
activins, inhibins, bone morphogenetic proteins, anti-Müllerian hormone, as well as growth and 
differentiation factors, is conserved through evolution and found in all multicellular organisms. 
Three highly homologous isoforms of TGF-β exist in humans: TGF-β1, TGF-β2 and TGF-β3. They 
share a receptor complex and signal in similar ways but their expression levels vary depending on 
the tissue, and their functions are distinct. Proteolytic cleavage, interaction with integrins or pH 
changes in the local environment are known to activate latent TGF-β and free active TGF-β for 
binding to its receptors at the cell membrane (Shi et al., 2011). 
1.3.1. REGULATION 
Each TGF-β ligand is synthesized as a precursor, which forms a homodimer that interacts with its 
latency-associated peptide (LAP) and a latent TGF-β- binding protein (LTBP), forming a larger 
complex called the large latent complex (LLC). The TGF-β activation process involves the release of 
the LLC from the ECM, followed by further proteolysis of LAP to release active TGF-β to its 
receptors. MMP-2 and MMP-9 are known to cleave latent TGF-β. In addition to MMPs, 
thrombospondin 1 (THBS1) is known to activate latent TGF-β. Binding to the extracellular domains 
of type I and II receptors, TGF- β actives the intracellular serine/threonine kinase domains of the 
receptors, facilitating the phosphorylation and the subsequent propagation of signalling by SMAD-
dependent pathway (Akhurst and Hata, 2012). 
1.3.2. BIOLOGICAL ACTIONS 
TGF-β is involved in a range of biological processes both during embryogenesis and in adult tissue 
homeostasis. 
- Inhibition of cell proliferation. TGF-β strongly inhibits the growth of many cell types, 
including epithelial, endothelial, haematopoietic and immune cells; moreover it has pro-
apoptotic and differentiation-inducing actions on epithelial cells. Together, these actions 
result in the context of tumour suppression. In oncology, many tumours are characterized 
by TGF-β growth-inhibitory effects, but this depends on the tumour type and the stage of 
tumour progression. In fact TGF-β may provide potent tumour-suppressive or tumour-
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promoting functions directly on the tumour cell, presumably by mediating differential gene 
expression programmes (Heldin et al., 2009). 
- Induction of epithelial–mesenchymal transition (EMT) and the myofibroblast phenotype. 
TGF-β can induce mesenchymal transition of both epithelial and endothelial cells. This has 
consequences for disease progression in both cancer and fibrosis. EMT increases cellular 
migration and invasive properties, as cell migration requires loss of cell–cell contacts and 
acquisition of fibroblastic characteristics. In breast and skin cancer, tumour cell EMT 
contributes to cancer progression as cells consequently become more migratory and 
invasive, and they can ultimately transition to a myofibroblastic phenotype, which leads to 
increase ECM elaboration and tissue contraction process (Derynck and Miyazono, 2008). 
- Extracellular matrix regulation. As TGF-β is widely documented to increase collagen 
synthesis and deposition by fibroblasts, TGF-β has become a central therapeutic target for 
different types of fibrosis. TGF-β activity and the synthesis of ECM proteins are regulated 
by several genes known to be important in driving fibrosis; these genes are directly 
regulated by TGF-β–SMAD signalling pathways. There is a reciprocal regulation of TGF-β by 
the ECM: latent TGF-β, bound to ECM components, such as fibronectin and fibrillin, is 
inactive until physiological or pathological processes initiate its release (Akhurst and Hata, 
2012).  
- Immune-suppression and inflammation. TGF-β has potent growth-suppressing activity on 
most precursor cells of the immune system, particularly T and B cells. TGF-β is a potent 
suppressor of T cell proliferation and an inducer of B cell apoptosis. Additionally, the ligand 
can alter the course of immune cell differentiation. During tumour progression, excess 
TGF-β suppresses immune surveillance by attenuating the anti-tumour functions of CD8+ T 
cells, CD4+ T cells and dendritic cells (Flavell et al., 2010) (Fig. 5). 
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Fig. 5: TGFβ signalling on leukocytes. Transforming growth factor-β (TGF-β) signalling can affect leukocytes 
with positive or negative effects. NK, natural killer. 
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1.3.3. TARGETED THERAPY IN HUMAN 
TGF-β has a biphasic action during tumourigenesis, suppressing it at early stages but promoting 
late-stage tumour progression. This is a paradigm for the action of TGF-β during disease 
progression in general, including that of fibrosis, inflammation and cardiovascular disease, and it 
derived by the fact that the normal function of this ligand is in the regulation of homeostasis. 
Therefor the main goal in cancer therapy is to downmodulate excessive levels of TGF-β ligands. In 
mouse gene knockout studies, two major concerns in TGF-β drug development against cancer 
have been the inadvertent inhibition of the tumour-suppressing function of TGF-β signalling and 
the development of adverse side effects unrelated to cancer, such as widespread inflammation, 
autoimmunity or cardiovascular defects (Larsson et al., 2001). Until now most clinical trials in 
oncology regard breast cancer, followed by glioblastoma. TGF-β signalling inhibitors are generally 
safe and may be efficacious in several clinical applications, especially in desperate cases such as 
end-stage cancer (Akhurst and Hata, 2012). Another objective regards cancer ‘stem cells’, or 
tumour-initiating cells. Several groups have now reported, in vitro and in vivo, that TGF-β induced 
EMT can drive tumour cells towards a more ‘stem cell-like’ phenotype (capacity to self-renew and 
to initiate and persistently propagate the entire tumour). It is important to note that, in cancer, 
the outcome of reduced TGF-β signalling may be highly dependent on the innate genetic 
background of the individual, especially when considering tumour microenvironment effects, such 
as immune surveillance (Akhurst and Hata, 2012). 
1.3.4. TGF-β IN DOG 
Little is known about  TGF-β in canine tumours and one study shows that TGF-β activity was high in 
the tumour-bearing dogs (Itoh et al., 2009); another one gives a possible role of tumour 
suppressor for TGF-β in the development of hepatocellular carcinoma in dogs (Grabarević et al., 
2009) and Klopfleisch and his colleagues (2010) suggest that loss of TGF-β-3 may have growth-
stimulatory effects in late-stage tumours, and loss of its expression, together with reduced TGFβR-
3 expression, may be associated with increased proliferative activity of canine mammary tumour 
similar to findings in human breast cancer.  
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1.4. PLATELET-DERIVED GROWTH FACTOR 
 
Members of the platelet-derived growth factor (PDGF) family are major mitogens for connective 
tissue cells, glial cells, and certain other cell types. Structurally they are homodimers of related A-, 
B-,C-, and D-polypeptide chains, and an AB heterodimer. PDGF isoforms exert their cellular effects 
by binding to α- and β-tyrosine kinase receptors (Fig. 6). PDGF was originally purified from human 
platelets. Its isoforms stimulate proliferation, survival, chemotaxis, and differentiation of cells. 
They have important functions during embryogenesis and in the adult during wound healing and 
in the control of interstitial fluid pressure. Over-expression of PDGF has been linked to several 
pathological conditions, including tumours and other conditions involving an excess cell 
proliferation, such as fibrotic conditions and atherosclerosis (Heldin and Westermark, 1999). 
 
Fig. 6. The preferences of PDGF family members for PDGFRs. There are two receptor subunits that are 
homo- or hetero-dimerized. PDGF-BB is the universal ligand. PDGF-AB and PDGF-CC assemble and activate 
the PDGFR-αα and PDGFR-αβ. PDGF-DD activates the PDGFRββ, and under certain circumstances the 
PDGFRαβ. PDGF-AA is the most selective member of the PDGF family and activates PDGFR-αα exclusively. 
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1.4.1. REGULATION 
Ligand binding induces dimerization of the receptors; the α-receptor binds all PDGF chains except 
the D-chain, whereas the β-receptor binds the B- and D-chains. Thus, the different PDGF isoforms 
induce different homo- and heterodimeric complexes of α- and β-receptors. In the dimeric 
receptor complexes, receptors phosphorylate each other in trans positions on specific tyrosine 
residues; finally members of the STAT family of transcription factors bind to activate PDGF 
receptors (Heldin, 2012). 
1.4.2. PDGF AND CANCER 
PDGF is often over-expressed in neoplasia and contribute to the growth of certain tumour types as 
well as to cells of the microenvironment of solid tumours, such as pericytes and smooth muscle 
cells of vessels and of stromal fibroblasts. Certain tumour cells expressing PDGF receptors produce 
PDGF isoforms, which stimulate cell growth and survival in an autocrine manner (Heldin and 
Westermark, 1999). The levels of expression of PDGF ligands as well as receptors are higher in 
more malignant tumours, suggesting that autocrine and paracrine effects of PDGF increase with 
degree of malignancy. Gliomas are probably the tumour type in which PDGF autocrine 
mechanisms are most important: nearly 30% of human gliomas show over-activity of PDGF 
receptor signalling. PDGF has also been implicated in other tumour types: in fact co-expression of 
PDGF and PDGF receptors has been reported in an AIDS-related Kaposi’s sarcoma and in 
meningioma. Moreover, an autocrine PDGF-BB/PDGFR-β loop was found to mediate survival of 
large granular lymphocyte leukaemia of both T- and NK-cell origin (Yang et a., 2010). 
In addition to classical autocrine stimulation, there are examples of mutations in the genes for 
PDGFRs, which cause their activation and promote tumourigenesis. Thus, in chronic 
myelomonocytic leukaemia (CMML), the kinase domain of PDGFR-β is fused to different partners. 
Analogously, in patients with idiopathic hypereosinophilia and systemic mastocytosis, the kinase 
domain of the PDGFR-α is fused to FIP1L1. In addition to the juxtaposition of the kinase domains of 
the receptors, the loss of regulatory sequences in the juxtamembrane and transmembrane 
domains is important for the increased autophosphorylation and initiation of signalling pathways 
promoting cell growth and survival. A majority of gastrointestinal stromal tumours (GISTs) have 
activating point mutations in Kit, a tyrosine kinase receptor for stem cell factor, which is 
structurally similar to PDGFRs (Heldin, 2012).  
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Epithelial cells normally do not contain PDGFRs. However, epithelial tumours can undergo EMT, 
changing in phenotype and making the tumour cells more invasive. In conjunction with EMT, PDGF 
and its receptors are induced. Interestingly, the metastatic potential of mammary epithelial 
tumours was shown to be dependent on an autocrine PDGF/PDGFRs loop. There are examples of 
stromal cells, such as smooth muscle cells, endothelial cells, and macrophages, which both can 
express PDGFRs and produce PDGF. However, it is not clear whether normal cells express PDGFRs 
and synthesize PDGF at the same time (Heldin, 2012). 
1.4.3. TARGETED THERAPY IN HUMAN 
In the last decades, the research in the field of tumour angiogenesis led to the development of a 
class of agents providing an effective inhibition of neovessels formation, through the blockade of 
VEGF-related pathways. More recently, the identification of several non-VEGF factors, such as 
PDGF, involved in tumour angiogenesis, in association with tumour progression, have emphasized 
the need to develop agents targeting multiple pro-angiogenic pathways. Besides the successful 
development of anti-VEGF drugs, novel agents targeting alternative angiogenesis-related 
pathways are being tested. Although it seems that the potential clinical usefulness of these novel 
compounds have been not yet fully investigated, sunitinib, sorafenib, pazopanib and other 
multikinase inhibitors, used in first line for advanced renal cell carcinoma, have certainly displayed 
encouraging results (Sennino  and  McDonald, 2012). 
1.4.4. PDGF IN DOG 
In veterinary oncology, PDGF has been investigated only in spontaneous canine astrocytomas, 
where increased PDGFRα expression was observed (Higgins et al., 2010); in canine osteosarcoma 
(Maniscalco et al., 2012), spontaneous canine hemangiosarcoma and cutaneous hemangioma (Asa 
et al., 2012).  
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2. AIM 
 
It is evident from the data presented in this background that primary tumours and their metastasis 
are complex interactions consisting of numerous cell types. In analysing tumours, the experiments 
are usually focused upon a single cell type or a single gene product within a cell. However, it is 
naive to think that individual cell types work in isolation within a complex system. Thus, a major 
area for advances in understanding the role of the microenvironment must incorporate a system 
biology approach in order to model these interactions and their evolution over time. Both 
individual and collective migration modes are presumably further regulated by heterologous 
interactions between tumour cells and reactive stromal cells of the tumour microenvironment. 
Cancer cells can alter their adjacent stroma to form a permissive and supportive environment for 
tumour angiogenesis, invasion and metastasis, and therefore tumour progression, producing a 
range of growth factors and proteases that modify this ‘reactive’ tumour stroma. 
A more comprehensive understanding of the molecular basis of diversity and adaptation of cell 
migration is therefore required to efficiently target cancer-cell motility and invasion. Little data 
exists for the biological and clinical role of growth factors and proteinases involved in tumour 
progression in domestic species. 
The aims of this present work are to define gene expression profiling and proteomic analysis of 
different growth factors (VEGF-TGF-β-PDGF) and matrix metalloproteinases. Their possible 
prognostic and predictive role, in association with their crosstalk, will be also analysed in four 
different canine tumours:  
- mammary tumour 
- cutaneous mast cell tumour 
- lymphoma 
- lymphoid leukaemia 
A better understanding of the tumour environment affecting cancer progression should provide 
new targets for the isolation and destruction of cancer cells via interference with the crosstalk 
established between cancer cells, host cells, and their surrounding extracellular matrix. 
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3. PHASE 1: Matrix metalloproteinases and their inhibitors in canine 
mammary tumours* 
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Adapted with the permission of “Biomed Central” from:  Aresu L, Giantin M, Morello E, Vascellari M, 
Castagnaro M, Lopparelli R, Zancanella V, Granato A, Garbisa S, Aricò A, Bradaschia A, Mutinelli F, Dacasto 
M. Matrix metalloproteinases and their inhibitors in canine mammary tumours. BMC Vet Res. 2011 Jul 
4;7:33. © 2011 BioMed Central Ltd. All rights reserved. 
PHASE 1: MMPs and their inhibitors in canine mammary tumours  Pag. 32 
BACKGROUND 
Mammary neoplasia is one of the most common tumours in dogs, and malignant types occur in 
approximately half of canine mammary tumours. Invasion and metastasis are typical features of 
carcinomas (Karayannopoulou et al., 2005). The mRNA expression of MMP-2, MMP-9, TIMP-1, 
TIMP-2 and TIMP-3 has been extensively studied in vivo and in vitro in various human tumours 
(Stetler-Stevenson et al., 1989; Urbanski et al., 1992; Muller et al., 1993; Bhuvarahamurthy et al., 
2006). In veterinary medicine, mRNA expression of these genes has been used to study canine 
neoplasia (Takagi et al., 2005; Nakaichi et al.,2007) and other diseases (e.g., meningitis-arteritis, 
chronic valvular disease, and arthritis)(Muir et al., 2007; Aupperle et al., 2009; Schwartz et al., 
2010), but their expression in canine mammary tumours has not been specifically documented. 
Evaluation of the activities of TIMP-1, TIMP-2 and TIMP-3 in canine mammary tumour samples by 
reverse zymography has shown that low activity can be correlated with a malignant phenotype 
(Kawai et al., 2006). Membrane type 1 MMP (MT1-MMP) was the first MT-MMP to be identified as 
a major physiological activator of pro-MMP-2 in humans (Davies et al., 1993). Studies of canine 
mammary tumours suggest that pro-MMP-2 activation requires the formation of a ternary 
complex that consists of the C-terminal domain of pro-MMP-2, TIMP-2 and MT1-MMP (Papparella 
et al., 2002). The important role of another MMP family member, MMP-13, has been 
demonstrated in breast cancer and colorectal cancer (Chang et al., 2009; Huang et al., 2010). In 
veterinary medicine, reports of MMP-13 expression are only available for inflammatory and 
degenerative diseases (House et al., 2007; Disatian et al., 2008). After the sequencing of the entire 
dog genome, microarray technology has been used to characterize different canine mammary cell 
lines, progestin-induced canine mammary hyperplasia and spontaneous mammary tumours (Rao 
et al., 2008; Klopfleisch et al., 2010; Król et al., 2010), but, in literature, no targeted gene 
expression profiling studies are available for spontaneous canine mammary tumours. 
AIM 
The aim of the first study is to analyse MMP-2, MMP-9, MMP-13, MT1-MMP and TIMP-2 
expression at both the mRNA and protein levels in canine mammary tumours including simple 
adenomas and carcinomas. The enzymatic activities of MMP-2 and MMP-9 are quantified by 
gelatin-zymography of the same homogenized tumour tissues and plasma from selected patients. 
Gene expression is evaluated also for TIMP-1, TIMP-3 and RECK. Moreover, the stromal 
compartments in these tumours are specifically evaluated. 
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METHODS 
Tissue sampling 
Fresh tissue samples were obtained from 35 dogs that underwent surgery for mammary neoplasia. 
The dogs underwent surgery due to evident disease, and the explicit consent of the owner was 
obtained. Excised tumour lesions were immediately divided into aliquots and stored under diverse 
conditions for different analytical techniques. For RNA isolation, aliquots of approximately 100 mg 
were immersed in RNAlater® solution (Applied Biosystems, Foster City, CA) and stored at -20°C 
until use. For histological examination and immunohistochemistry, the tissue was formalin-fixed 
and paraffinembedded. For gelatin-zymography, aliquots of up to 100 mg were frozen at -20°C 
until use. 
Gene expression 
Total RNA was isolated from control mammary glands, which were obtained from pathogen-free 
adult Beagles generously provided by GlaxoSmithKline Manufacturer S.p.A. (Verona, Italy) that had 
been used for other experimental purposes and 35 pathological samples using TRIzol® (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions. The samples were purified with a 
classical phenol-chloroform extraction step. The total RNA concentration and quality were 
measured with a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, 
DE) and by denaturing gel electrophoresis. First-strand cDNA was synthesized from total RNA using 
the High Capacity cDNA Transcription Kit according to the manufacturer’s protocol (Applied 
Biosystems, Foster City, CA). The generated cDNA was used as the template for quantitative real-
time RT-PCR (qRT-PCR) in a LightCycler 480 Instrument (Roche Diagnostics, Basel, Switzerland) 
using standard PCR conditions. The qRT-PCR reactions consisted of 1X LightCycler 480® Probe 
Master (Roche Diagnostics, Basel, Switzerland), 300 or 600 nM forward and reverse primers (the 
primer combination and final concentrations were optimized during assay setup), 100 nM human 
Universal Probe Library (UPL) probe (Roche Diagnostics) and 5 ng cDNA. The primers and human 
UPL probes shown in Table 1 were designed using the UPL Assay Design Centre web service. 
Calibration curves using a four-fold serial dilution of a cDNA pool revealed PCR efficiencies close to 
two and error values less than 0.2. Canine transmembrane BAX inhibitor motif containing 4 (CGI-
119) and Golgin a 1 (GOLGA1) were chosen as reference genes for the absence of pathological 
statedependent differences in mRNA expression (Rao et al., 2008). Their amplification efficiencies 
were approximately equal to that of the target genes; moreover, no statistically significant 
difference was observed in their expression profiles between healthy and pathological samples. 
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The ΔΔCt method (Livak and Schmittgen, 2001) was used for the relative quantification of mRNA. 
Relative quantification (RQ) values were ultimately expressed as the fold change, such as RQ 
sample/control group mean RQ ratio, assuming that the control mammary gland mean RQ was 
equal to 1. Statistical analysis of the gene expression data was performed using the Kruskal-Wallis 
test followed by Dunn’s post test. The correlation analysis of the target gene mRNA data was 
performed using a Spearman nonparametric test. In both analyses, GraphPad InStat 2.01 software 
(San Diego, California, USA) was used, and a p value < 0.05 was considered significant. Finally, 
Grubbs’ test was used to identify outliers. 
 
Table 1: Primer sequences and human UPL probes used for qRT-PCR amplification 
Genes 
  
Accession number 
 
Primer sequence (5’-3’) Human  
UPL probe 
MMP2 [GenBank:XM_535300.2] F: gggaccacggaagactatga 29 
     R: atagtggacatggcggtctc 
MMP9 [GenBank:NM_001003219.1] F: tgagaactaatctcactgacaagca 6 
     R: gctcggccacttgagtgta 
MMP13 [GenBank:XM_536598.2] F: ctcttcttctcgggaaacca 50 
     R: gcctggggtagtctttatcca 
MT1-MMP [GenBank:XM_843664.1] F: gatctgaatgggaatgacatctt 
76 
    R: gatggccgagggatcatt 
TIMP1 [GenBank:NM_001003182.1] F: cagggcctgtacctgtgc 112  
     R: cctgatgacgatttgggagt 
TIMP2 [GenBank:NM_001003082.1] F: atgagatcaagcagataaagatgttc 93 
     R: ggaggaaggagccgtgtag 
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TIMP3 [GenBank:XM_538410.2] F: tgctgacaggccgcgt 14 
     R: gcagttacagcccaggtga 
RECK [GenBank:NM_001002985.1] F: aaggggtgtctgtctggagat 97 
     R: cccaatttgcaaccttgaac 
CGI-119 [GenBank:XM_531662.2] F: tctacaatctaagagagatttcagcaa 15  
     R: ttcctgacaagcacaaaatcc 
GOLGA-1 [GenBank:XM_537849.2] F: ggtggctcaggaagttcaga 149  
     R: tatacggctgctctcctggt 
 
Immunohistochemistry 
To analyse the expression of the MMP-2, MMP-9, MMP-13, MT1-MMP and TIMP-2 proteins by 
immunohistochemistry, contiguous 4 μm sections were cut from blocks of formalin-fixed, paraffin-
embedded tissue, and the sections were placed on charged slides. After deparaffinization, the 
primary antibody incubation step for all antibodies was performed by an automated system 
(Ventana Medical Systems, Tucson, AZ). The pertinent antibody details are summarized in Table 2. 
The remainder of the staining procedure included incubation with a biotinylated anti-mouse 
secondary antibody, the diaminobenzidine substrate and a haematoxylin counterstain was 
performed using the Ventana ES automated immunohistochemistry system. Negative control 
slides were incubated with isotype-matched immunoglobulin in parallel with each staining batch 
to confirm the specificity of the antibodies. For each antibody, cases were semi-quantified for each 
protein-stained area. The intensity and the percentage of immunoassayed tumour cells were 
analysed. Each slide was scanned with a 400 × power objective in ten fields per slide, and the fields 
were selected by searching for protein-stained areas. A section was considered negative or 
positive according to the absence or presence of cytoplasmic staining. An intensity score of 0 was 
given if no staining was detected, 1 if there was weak to moderate staining, 2 if moderate to 
strong staining was present, and 3 if strong staining was detected. A total score for each examined 
field was obtained by multiplying the intensity score by the percentage of immunoassayed cells. A 
final ratio was obtained after averaging the ten selected fields. An image analysis system that 
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consisted of an Olympus BX51 microscope and software analysis (analySIS, Soft imaging system, 
Münster, Germany) was used. Furthermore, the immunoreactivity of each antibody was 
separately recorded for tumour and stromal cells in ten fields (400× power objective), and the final 
result was expressed as the average percentage from ten fields. For statistical analysis, dog 
tumours were subdivided into two groups: benign and malignant. Immunostaining score values for 
each protein were expressed as a median (range). The Mann-Whitney test was used to compare 
the immunostaining scores. Differences in percentages were calculated with the Chisquare test. 
The program SPSS 17.00 (SPSS Inc, Chicago, IL, USA) was used for all calculations.  
 
Table 2: Details of antibodies  
Antigen Source Clone Dilution Manufacturer 
MMP-9 Human MAB 3309 1:1000 Chemicon (Millipore)  
MMP-2 Human Ab-7 1:400 Neomarkers, Fremont, USA 
TIMP-2 Human MAB 3317 1:1000 Chemicon (Millipore) 
MMP-13 Human VIIIA2 1:100 Millipore Co., Billerica, USA 
MT1-MMP Human - 1:200 Millipore Co., Billerica, USA 
 
 
Zymography  
MMP-2 and MMP-9 activity was studied by zymography, which reveals the gelatinase activity of 
latent proenzymes (zymogens) and mature MMPs. The homogenized tissue was centrifuged at 
1500 rpm for 10 min, and the protein concentration of the supernatant was measured. The sample 
protein concentration was adjusted to 1 mg/ml, and 5 μl was diluted 1:1 in sample buffer; the final 
10 μl sample was subjected to electrophoresis on an 8% SDS-PAGE gel copolymerized with 0.1% 
gelatin. Following electrophoresis, the gel was incubated for 1 h at room temperature in a 2.5% 
Triton X-100 solution and then at 37°C for 16 h in 0.5 M Tris-HCl buffer, pH 7.4, with 10 mM CaCl2. 
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The gels were stained with 0.1% Coomassie Brilliant Blue R-250 and de-stained with 30% methanol 
and 10% acetic acid. Gelatinolytic activities were detected as unstained bands against the 
background of Coomassie- stained gelatin. Culture medium conditioned by A2058 melanoma cells 
was used as a control to identify the pro-MMP-9 gelatinolytic band, while conditioned media from 
HT1080 fibrosarcoma cells was used for the active forms of MMP-2 and MMP-9 and small 
amounts of the pro-MMP-2 (Davies et al., 1993). The amount of MMP-9 in 20 μl of the A2058 
melanoma cell-conditioned media was defined as 100 arbitrary units (a.u.). The MMP-2 activity in 
20 μl of HT1080 fibrosarcoma cell-conditioned media was defined as 100 a.u. The bands were 
quantified using an image analyser system that consisted of a GelDoc 2000 and Quantity One 
software (BioRad, Hercules, CA, USA). Peripheral blood samples were collected from 14 dogs 24 h 
before surgery. The plasma was obtained by blood sample centrifugation and stored at -20°C, and 
10 μl was used for analysis. The plasma concentrations of MMP-2 and MMP-9 were evaluated by 
gelatin-zymography. The gelatinolytic activity was defined as the arbitrary optical density value of 
the sample relative to the optical density value of the control plasma from healthy dogs. 
 
RESULTS 
This study included 35 dogs with a median age of 9.9 years. Of the 35 tumours, 13 were simple 
adenomas, and 22 were simple carcinomas, according to the WHO classification system for canine 
mammary tumours (Misdorp, 2002). 
Gene expression 
The mRNA expression of MMP-2, MMP-9, MMP-13, MT1-MMP, TIMP-1, TIMP-2, TIMP-3 and RECK 
in mammary tumours and healthy mammary glands was investigated using a qRT-PCR approach. 
The overall results are reported in Table 3. All of the target genes were expressed in the control 
and tumour samples, with the exception of MMP-13, which was weakly expressed or not amplified 
in approximately half of the tumour samples (16 of 35 dogs). No statistically significant differences 
were observed for MMPs and inhibitors, particularly between benign and malignant tumours. 
Spearman correlation analysis was performed to identify potential relationships between MMPs 
and their preferential inhibitors at the transcriptional level and between MMP-2 and its well-
known specific activator (MT1-MMP). Positive correlations were observed between MMP-2 and 
MT1-MMP (r = +0.52, p < 0.01), MMP-2 and TIMP-2 (r = +0.47, p < 0.01), MT1-MMP and TIMP-2 (r 
= +0.39, p < 0.05), and MMP-9 and TIMP-1 (r = +0.56, p < 0.001). 
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Table 3: MMPs and inhibitors mRNA expression in control mammary glands, benign and malignant 
mammary tumours 
Gene Control Benign Malignant 
MMP-2 1.00 ± 0.46 1.01 ± 0.18 0.76 ± 0.12 
MMP-9 1.00 ± 0.30 9.95 ± 4.40 7.23 ± 1.58 
MMP-13 1.00 ± 0.28 2.08 ± 0.70 1.27 ± 0.25 
MT1-MMP 1.00 ± 0.24 13.26 ± 6.09 2.82 ± 0.64 
TIMP-1 1.00 ± 0.17 4.96 ± 1.27 3.97 ± 0.66 
TIMP-2 1.00 ± 0.34 0.49 ± 0.09 0.60 ± 0.09 
TIMP-3 1.00 ± 0.35 4.16 ± 1.62 2.38 ± 0.65 
RECK 1.00 ± 0.52 3.41 ± 1.77 0.51 ± 0.10 
Data are expressed in –fold changes (arbitrary units) as mean ± SEM. Statistical analysis: Kruskal-Wallis test 
+ Dunn’s post test. 
 
Immunohistochemistry 
Immunohistochemical staining revealed that MMP-2 and MMP-9 were present in all of the 
tumours examined. The two MMPs were strongly localized in the cytoplasm of the tumour 
epithelial cells (Fig. 1a, b,c). There were significant differences in the immunohistochemical score 
values for these two markers in benign and malignant neoplasia (Table 4). An intense 
immunoreaction was especially evident for MMP-2 in carcinomas, while the difference in MMP-9 
immunolabelling in adenomas and carcinomas was lower. The MT1-MMP protein was detected in 
21 tumours, and its expression was higher in malignant tumours. Tissue leukocytes and plasma 
cells stained positive for MMP-2 and MMP-9 as well as for MT1-MMP, and it was considered a 
positive control. Immunohistochemical staining revealed that TIMP-2 and MMP-13 were more 
highly expressed in simple adenomas than in simple carcinomas (Fig. 1e, f). The magnitude of the 
immunohistochemical detection of MMP-2, MMP-9 and MT1-MMP varied in the fibroblasts of the 
PHASE 1: MMPs and their inhibitors in canine mammary tumours  Pag. 39 
stromal compartment. The staining intensity for MMP-2 and MT1-MMP was stronger in the 
fibroblasts closest to the epithelial tumour cells in the malignant tumours (Fig. 1d), while 
immunolabelled fibroblasts by the two proteins were scattered in the adenomas (Table 5). The 
percentage of fibroblasts that were positive for MMP-9 staining was lower than the percentage of 
those positive for MMP-2 in carcinomas. The percentage of TIMP-2- and MMP-13-positive 
fibroblasts was higher in adenomas than in carcinomas. The immunohistochemical data are 
summarized in Tables 4 and 5. 
 
Table 4: Immunostaining score values for MMPs and TIMP-2 expressed as median (range) in 
benign and malignant mammary tumours 
 Benign Malignant P 
MMP-2 58.5 (45.4-145.5) 179.4 (120.1-267.3) 0.002 
MMP-9 78 (26.8-189) 101.1 (34.3-213.9) 0.01 
MMP-13 84.2 (0-198.2) 45.3 (0-101.2) 0.005 
MT1-MMP 65.3 (0-230.2) 132.1 (34.2-221.2) 0.002 
TIMP-2 74.3 (21.2-201.2) 48.9 (0-136.6) n.s. 
n.s.= not significant 
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Table 5: Immunohistochemical score for epithelial tumour cells and fibroblasts expressed as 
average percentage from ten fields in benign and malignant mammary tumours 
 Benign (%) Malignant (%) P 
MMP-2    
Tumour cells 88.6 67.5 0.05 
Fibroblasts 11.4 32.5  
MMP-9    
Tumour cells 84.1 89.4 0.002 
Fibroblasts 15.9 10.6  
MMP-13    
Tumour cells 56.4 65.9 n.s. 
Fibroblasts 43.6 34.1  
MT1-MMP    
Tumour cells 80.3 55.8 0.001 
Fibroblasts 19.7 44.2  
TIMP-2    
Tumour cells 53.3 79.6 n.s. 
Fibroblasts 46.7 20.4  
n.s.= not significant 
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Fig. 1. Canine mammary tumours. (a) Epithelial tumour cells and stromal fibroblasts with intense MMP-2 
immunopositivity in a carcinoma. (b) Epithelial tumour cells with weak MMP-2 immunopositivity in an 
adenoma. (c) Epithelial tumour cells and fibroblasts strongly MMP-9-immunolabelled in a carcinoma. (d) 
Epithelial tumour cells and stromal fibroblasts with intense MT1-MMP immunopositivity in a carcinoma. (e) 
Moderate TIMP-2 immunostaining in epithelial tumour cells in an adenoma. (f) TIMP-2 antibody-negative 
epithelial tumour cells in a carcinoma. (Immunohistochemistry, 200×). 
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Zymography 
For each tumour sample, the active and inactive forms of MMP2 and MMP-9 were measured by 
their gelatinolytic activities (Fig. 2). The activities of MMP-2 and MMP- 9 were calculated in 
arbitrary units per 10 ng of protein. The pro-MMP-2 band was detected in all samples examined 
(adenoma and carcinoma). The activity of the carcinoma samples ranged between 16.7 and 59.9 
units, while the activity of the adenoma samples ranged between 3.5 and 15.7 units. Bands for the 
active form of MMP-2 were found in 94% of the carcinoma samples and 17% of the benign tumour 
samples. In the simple carcinomas, the MMP-2 activity ranged between 47.4 and 87.5 units. The 
pro-MMP-9 band was expressed in all samples examined by gelatin-zymography. The activity 
range of the carcinoma samples varied greatly (from 7.5 to 106.4 units), while the activity range of 
the twelve benign samples was between 20.5 and 41.2 units. Only eight carcinomas exhibited 
bands for the active form of MMP-9. The activity was similar among the samples, ranging from 
34.3 to 40.3 units. No bands were observed for the active form of MMP-9 in adenomas. The 
activities of both the pre- and activated forms of MMP-2 and MMP-9 were measured by gelatin-
zymography of the plasma of fourteen dogs with mammary tumours and three healthy control 
dogs. A representative gel is shown in Fig. 3. Regardless of the tumour type, the band for pro-
MMP-9 was significantly more evident in the plasma of dogs with tumours than in healthy dogs. 
The activated form of MMP-9 was not observed in healthy dogs but was present in all of the dogs 
with tumours. Pro-MMP-2 was detectable in the plasma of all dogs with tumours and also in 
control dogs with no difference in the level of expression, and the MMP-2 activated form was not 
detectable in either case. 
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Fig. 2. Zymographic assay of gelatinase activity in malignant (M) mammary neoplasia, in benign (B) 
mammary neoplasia and in the control (C). Bands corresponding to latent and active forms of MMP-9 and 
to latent and active forms of MMP-2 were observed in carcinomas (M), while bands corresponding to latent 
forms of MMP-9 and MMP-2 were observed in adenomas (B). HT1080 fibrosarcoma cells (C) were used as 
the control for pro-MMP-9, pro-MMP-2 and active form of MMP-2. 
 
 
 
Fig. 3. Zymographic assay of gelatinase activity in pre-surgery plasma samples. (M = malignant mammary 
neoplasia, B = benign mammary neoplasia, C = control, N = normal dog). Bands corresponding to pro-
MMP-2, pro-MMP-9 and active form of MMP-9 were observed in dogs with adenomas and carcinomas (B, 
M). Bands corresponding to pro-MMP-9 and pro-MMP-2 were observed in the control dog, and A2058 
melanoma cells (C) were used as the control for active MMP-9. 
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DISCUSSION 
In recent years, investigations of tumour growth have focused on the surrounding stroma in 
different tumours, considering important for cellular invasion, tumour growth and epithelial 
mesenchymal transformation (Bergamaschi et al., 2008; Zhang et al., 2009). The engagement of 
the neoplasia with a ‘reactive stroma’ provides structural and vascular support for tumour growth 
and also leads to tissue reorganization and invasiveness (Egeblad and Werb, 2002). MMPs play an 
important role in this mechanism by degrading the stromal connective tissue and basement 
membrane components. In addition, MMPs impact tumour cell behaviour in vivo because of their 
ability to cleave growth factors, cell adhesion molecules, and chemokines. The proteolytic activity 
of MMPs can be regulated at different levels, including gene expression, the conversion of the 
zymogen to the active enzyme, and by the presence of specific inhibitors. Among MMPs, MMP-2 
and MMP-9 have mainly been associated with malignant tumour progression and metastasis in 
both human and canine tumours (Papparella et al., 2002; Nakaichi et al., 2007; Vizoso et al., 2007). 
In this study, the mRNA and protein levels of MMP-2, MMP-9, MMP-13, MT1-MMP and TIMP-2 in 
benign and malignant mammary tumours were thoroughly analysed. TIMP-1, TIMP-3 and RECK 
mRNA expression was analysed focusing on the expression of different MMP proteins in stromal 
fibroblasts to identify a possible role in canine mammary tumours. MMP-2 mRNA was expressed 
in all pathological samples, but no statistically significant differences were observed between 
benign and malignant tumours. On the contrary, at the protein level, immunohistochemistry 
identified higher MMP-2 expression in carcinomas; gelatin-zymography confirmed differences in 
MMP-2 production between adenomas and carcinomas (p < 0.05, data not shown). In particular, 
significant bands were observed for both the inactive and active forms of MMP-2 in simple 
carcinomas, while simple adenomas were characterized by minimal bands that corresponded to 
pro-MMP-2, suggesting that this enzyme is important during the infiltration process. Pro-MMP-2 
may be converted to the active form during the infiltration process in malignancy; intense 
gelatinolytic activity has been described as necessary for malignant transformation (Tokuraku et 
al., 1995). These data are comparable to those from human studies. In human lung and gastric 
carcinomas, the MMP-2 activation ratio is enhanced; in canine tumour studies, higher MMP-2 and 
MMP-9 levels were observed in tumours than in inflammation, in malignant tumours than in 
benign tumours, in sarcomas than in carcinomas and in the advancing edge of canine malignancies 
than in the centre of canine tumours (Loukopoulos et al., 2003). In this study a band 
corresponding to active MMP-2 was observed in only two adenomas, and histological examination 
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of these two samples showed an intense stromal reaction close to the tumour. Activation of the 
zymogen form of MMP-2 is a cell surface event that is mediated by members of the membrane-
type subfamily of MMPs, and MT1-MMP is the first physiological activator of pro-MMP-2 (Lambert 
et al., 2004). In this study, the immunohistochemical data for MMP-2 and MT1-MMP were 
comparable for both adenomas and carcinomas. MT1-MMP was distributed similarly to MMP-2 in 
malignant tumours and was reduced in benign tumours. Despite the opposing results obtained for 
mRNA and protein expression in benign and malignant mammary tumours, a close relationship 
between MMP-2 and MT1-MMP was observed at the pre-transcriptional level. Interestingly, 
immunohistochemistry showed an intense reaction for the stromal fibroblast component, with a 
significant increase in MMP-2 (p = 0.05) and MT1-MMP (p = 0.001) expression in the fibroblasts 
associated with carcinoma. MT1-MMP expression generally correlates well with MMP-2 activation 
in various human cancers, suggesting that MT1-MMP plays an important role in cancer cell 
invasion (Guedez et al., 1998; Takagi et al., 2005). This presumably occurs through direct ECM 
cleavage by MT1- MMP and perhaps via MT1-MMP-mediated pro-MMP-2 activation. Both MMP-2 
and MT1-MMP have previously been detected by immunohistochemistry in canine mammary 
carcinomas (Papparella et al., 2002). However, the results obtained here were similar, suggesting 
that peritumour stromal cells may be a possible source of MMP-2 and MT1-MMP and promoters 
of invasion. Further studies in different tumours or in vitro are needed to support this hypothesis. 
qRT-PCR analysis revealed a high level of mRNA expression for MMP-9 in both benign and 
malignant mammary tumours. Epithelial cell immunoreactivity with the anti-MMP-9 antibody was 
observed in all tumours. MMP-9 positivity was higher in malignant tumours than in adenomas, 
confirming previous observations in human breast cancer (Del Casar et al., 2009) and canine 
mammary tumours (Hirayama eta l., 2002). Immunohistochemistry also revealed that the stromal 
fibroblasts had a minimal capacity to synthesize MMP-9. The enzyme activity was analysed by 
gelatin zymography; active MMP-9 form was not observed in any of the simple adenomas, and 
only eight carcinomas had a band for the active MMP-9 form, while all of the examined tumours 
had variable pro-MMP-9 gelatinolytic activity (p < 0.01 data not shown). The limited presence of 
the active form of MMP-9 may indicate a minor role for this gelatinase within the tumour, and it 
appears to be of little prognostic or pathogenetic value, as observed in canine tumours (Hirayama 
et al., 2002). TIMP-2 plays a double role, as both inhibitor and activator of MMP-2. Surprisingly, 
high TIMP-1 and TIMP-2 mRNA levels can predict adverse prognosis and be correlated with 
tumour aggressiveness in several different human cancers, including breast cancer (Ring et al., 
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1997; Vizoso et al., 2007). In the present study, neither the mRNA nor the protein levels of TIMP-2 
expression correlated with malignancy. MMP-13 was also evaluated. At the pretranscriptional 
level, it was expressed only in half of pathological samples, and immunohistochemistry revealed a 
higher level of expression in benign tumours than in malignant tumours. MMP-13 expression has 
previously been evaluated only in human tumours, for which MMP-13 involvement in tumour 
invasiveness was unclear (Freije et al., 1994). MMP-2 and MMP-9 plasma levels have been 
reported to be elevated in patients with various types of cancer. Plasma gelatinolytic activity in 
dogs was estimated by gelatin zymography in this work. Pro-MMP-9 and pro-MMP-2 were 
significantly concentrated in the plasma of all of the dogs, and bands for the latent forms were 
present in both animals with adenoma and animals with carcinoma. Moreover, the active form of 
MMP-9 was present in the plasma of all of the dogs with tumours with no differences in 
concentration between benign and malignant neoplasia. These data could indicate that the plasma 
levels of active MMP-9 are consistent with a proteinase activity that is due to the presence of an 
“ongoing disease,” and MMP-9 plasma levels may be a feasible method for detecting neoplastic 
growth in dogs in the future. TIMP-1, TIMP-3 and RECK mRNA expression were also evaluated and 
no statistically significant differences were observed among the groups. Contrasting results are 
reported in literature: microarray studies in dogs have shown that TIMP-1 and TIMP-3 are 
inhibited in progestin-induced canine hyperplasia relative to normal mammary glands (Rao et al., 
2009). Besides, a qRT-PCR study of RECK mRNA expression in various spontaneously developing 
canine tumours showed that expression levels were low in the majority of tumour tissues relative 
to normal tissues; however, in some neoplasia, RECK expression was higher than in the controls 
(Takagi et al., 2005). To exert its MMP inhibitory or activating role, TIMP-1 binds preferentially to 
MMP-9, and TIMP-2 binds to MMP-2 (Stetler-stevenson et al., 1989; Declerck et al., 1991). This 
relationship was confirmed in this study by the statistically significant correlations that were found 
between MMP-2 and TIMP-2, MMP-9 and TIMP-1 and MT1-MMP and TIMP-2 mRNA. The 
observed discrepancy between the mRNA and protein data has also been described by other 
studies (Caenazzo et al., 1998). Enzyme accumulation that is not accompanied by an increase in 
mRNA could be due to a feedback mechanism that shuts off mRNA expression after the secretion 
and/or binding of the protein. In addition, the samples used may not be representative (Caenazzo 
et al., 1998). Extracting and amplifying mRNA from cells obtained through the laser capture 
microdissection of the same formalin-fixed tissue that was used for immunohistochemistry might 
better clarify the mRNA/protein expression discrepancy observed in the present study. In 
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conclusion, the involvement of MMP-2, MT1-MMP, MMP-9 and various TIMPs was evaluated in 
canine mammary tumours, with an emphasis on the stromal compartment. The present work 
opens the possibility of developing new therapies and supports the use of the dog as an animal 
model in this field for studying the role of MMP-2 and MT1-MMP in the mechanism of cancer. 
MMPs may be target molecules of the switch mechanism that leads to the progression of 
carcinomas from adenomas. 
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4. PHASE 2: Expression of Matrix Metalloproteinases, Tissue Inhibitors of 
Metalloproteinases and Vascular Endothelial Growth Factor in Canine Mast 
Cell Tumours* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Adapted with the permission of “Elsevier” from: Giantin M, Aresu L, Benali S, Aricò A, Morello EM, 
Martano M, Vascellari M, Castagnaro M, Lopparelli RM, Zancanella V, Granato A, Mutinelli F, Dacasto M. 
Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases and vascular endothelial 
growth factor in canine mast cell tumours. J Comp Pathol. 2012 Nov;147(4):419-29. doi: 
10.1016/j.jcpa.2012.01.011. Epub 2012 Apr 19. © 2012 Elsevier Ltd. All rights reserved. 
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BACKGROUND 
Mast cell tumours (MCTs) are the most common cutaneous tumour of the dog (Thamm and Vail, 
2007) and are always considered potentially malignant, but their true metastatic potential is not 
entirely known (Welle et al., 2008). Currently, the prognostic significance of MCT is assigned 
through histological grading, but numerous studies have shown significant differences between 
well- and poorly-differentiated MCTs in terms of survival times and disease-free intervals. In 
particular, the prognosis for intermediate MCT (grade 2) is difficult to predict: the tumour might 
behave in a benign fashion or recur and metastasize. Well-differentiated tumours have a 
metastatic rate of <10%, intermediate tumours are considered low to moderate in metastatic 
potential and undifferentiated tumours have a much higher metastatic rate (55-96%; Welle et al., 
2008). Uncontrolled cellular proliferation plays a significant role in the progression of canine MCTs 
(Sakai et al., 2002; Scase et al., 2006; Webster et al., 2007; Gil da Costa et al., 2007). Despite these 
issues, information about ECM degradation and vascular angiogenesis in canine cutaneous MCT is 
sparse. MMPs have been evaluated only at the catalytic activity level through gelatin zymography 
(GZ) in samples from grade 2 and 3 tumours (Leibman et al., 2000) and VEGF has been detected at 
the protein level by immunohistochemistry (IHC) (Mederle et al., 2010) and by enzyme linked 
immunosorbent assay (ELISA) analysis (Patruno et al., 2009). 
AIM 
Thus, in order to better understand the role of ECM degradation and angiogenesis in canine MCTs 
of different histological grades, the aim of the present study is to evaluate the mRNA and protein 
expression of MMP-2, MMP-9, MT1- MMP, TIMP-2 and VEGF-A in MCTs subdivided by histological 
grade (Patnaik et al., 1984). The catalytic activities of both latent and active forms of MMP-2 and 
MMP-9 are also evaluated. 
 
METHODS 
Case Selection and Tissue Sampling 
Fresh tissue samples were obtained from 35 dogs that underwent surgery for MCT. The consent of 
the owners to use the tissues for research purposes was obtained. Only samples of suitable size 
and quality were included in the study. After excision of the entire tumour, multiple samples (50-
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100 mg) were collected from the central core of the mass. For total RNA isolation, aliquots were 
immersed in RNAlater® solution (Applied Biosystems, Foster City, California, USA) and stored at -
20°C until used. For GZ, aliquots were frozen at -20°C until used. The remaining tissue was 
formalin-fixed and paraffin wax-embedded for microscopical examination and IHC.  
Gene Expression  
Total RNA isolation, cDNA synthesis, primers, calibration curve data and the formulation of final 
value are reported in Phase 1. Canine VEGF-A (GenBank reference sequences: NM_001003175.2, 
NM_001110502.1 and NM_001110501.1) was amplified with 50-CGT GCC CAC TGA GGA GTT-30 
(forward primer, 300 nM final concentration) and 50- GCC TTG ATG AGG TTT GAT CC-30 (reverse 
primer, 300 nM) and human Universal Probe Library (UPL) probe number 9 (100 nM), while canine 
MMP-2, MMP-9, MT1-MMP, TIMP-2 and the reference genes transmembrane Bcl-2-associated X 
protein inhibitor motif containing 4 (CGI-119) and golgin A1 (GOLGA-1) were amplified with the 
primer pairs and UPL probes reported in Aresu et al. (2011).  
Immunohistochemistry 
The details of the immunohistochemal performance, the antibodies and the labelling valuation are 
described in Phase 1. Also a polyclonal rabbit antiserum specific for VEGF (Santa Cruz 
Biotechnology Inc., Santa Cruz, California, USA; diluted 1 in 200) was also used.  
Gelatin Zymography 
Gelatine zymography performance and the quantification of bands are reported in Phase 1. 
Statistical Analysis 
Statistical analysis of the gene expression and GZ data was performed using the non-parametric 
Kruskal-Wallis test followed by Dunn’s post test. The correlation between target gene mRNA data 
and between mRNA and protein activity results was performed using a Spearman non-parametric 
test. For all of these analyses, GraphPad InStat 2.01 software (San Diego, California, USA) was used 
and a p value < 0.05 was considered significant. To compare the IHC scores, differences in 
percentages were calculated with the Chi-square test. The SPSS 17.00 (SPSS Inc., Chicago, Illinois, 
USA) programme was used. 
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RESULTS 
Case Selection  
The study included samples from 35 MCTs from 35 dogs with a median age of 7.9 ± 2.7 years. Of 
the 35 tumours, seven were grade 1, 22 were grade 2 and six were grade 3. Male (14; three 
neutered) and female (17; two neutered) dogs were included in the study and in four cases the 
gender was not recorded. The following breeds were represented: crossbred (10), boxer (6), 
Labrador retriever (5), dogo Argentino (2), golden retriever (2), American Staffordshire bull terrier 
(1), dachshund (1), beagle (1), Boston terrier (1), cocker spaniel (1), Dalmatian (1), dogue de 
Bordeaux (1), rottweiler (1), English setter (1) and Siberian husky (1). 
Gene Expression 
All of the target genes were expressed in each MCT sample (Table 1). Between tumour grades, 
significant differences were found only for TIMP-2 where less TIMP-2 mRNA was found in grade 3 
compared with grade 2 tumours (p < 0.05). In contrast, there was a progressive, but not 
significant, increase in MMP-9 and VEGF-A expression with increasing histological grade. MMP-2 
and its specific activator (MT1-MMP) showed the same gene expression profile (r = +0.91, p < 
0.0001; Fig. 1). The MMP-2:TIMP-2 and MMP-9:TIMP-1 mRNA ratios were also determined. 
Progressive, but not significant, increases in both ratios were observed with increasing tumour 
grade (Fig. 2). 
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Table 1: MMP-2, MMP-9, MT1-MMP, TIMP-2 and VEGF-A mRNA expression 
 
mRNA expression (a.u.) 
  Grade 1 Grade 2 Grade 3 
MMP-2 2.54 ± 0.68 7.45 ± 3.50 2.03 ± 1.61 
MMP-9 0.62 ± 0.20 1.27 ± 0.39 5.66 ± 3.67 
MT1-MMP 1.19 ± 0.22 3.43 ± 1.42 1.40 ± 0.66 
TIMP-2 1.14 ± 0.29 1.69 ± 0.25 c 0.54 ± 0.21 
VEGF-A 0.86 ± 0.37 1.56 ± 0.42 1.92 ± 0.75 
Data are expressed as the mean ± standard error. 
a, b, c Significant differences between grade 1 and 2, grade 1 and 3 and grade 2 and 3, respectively 
(Kruskal-Wallis test followed by Dunn’s post test; c: p< 0.05). 
 
 
 
Fig. 1. Spearman correlation analysis between MMP-2 and MT1-MMP mRNA expression. 
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Fig. 2. (A) MMP-2:TIMP-2 and (B) MMP-9:TIMP-1 mRNA ratios in grade (G) 1, 2 and 3 MCTs. Data 
(mean± standard error) are expressed in a.u.. Statistical analysis: Kruskal-Wallis test followed by 
Dunn’s post test. 
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Immunohistochemistry  
MMP-2 and MMP-9 were present in all of the tumours examined (Table 2). Both molecules were 
localized to the cytoplasm of mast cells, while eosinophils appeared negative. MMP-9 expression 
was diffuse, while MMP-2 expression was multifocal (Fig. 3). Significant differences in the IHC 
scores were observed for MMP-9 between the three grades of MCT (p< 0.05). The most intense 
expression was in grade 3 MCTs (Fig. 4 and Fig. 5). The same behaviour was also observed for 
MMP-2, but this did not reach statistical significance (Fig. 3 and Fig. 5). MT1-MMP protein was 
observed in all tumours with cytoplasmic immunolabelling of few scattered neoplastic cells (data 
not shown). MT1-MMP expression increased with tumour grade without reaching statistical 
significance. In contrast, TIMP-2 expression was stronger in grade 1 than in grade 3 MCTs (p < 
0.01) (Fig. 6 and Fig. 5). Finally, VEGF-A expression was stronger in grade 3 than in grade 1 MCTs (p 
< 0.001; Fig. 7 and Fig. 5). Labelling was mainly of the cytoplasm of neoplastic cells, in particular 
those cells adjacent to blood vessels. 
 
Table 2: MMP-2, MMP-9, MT1-MMP, TIMP-2 and VEGF-A IHC 
IHC score 
  Grade 1 Grade 2 Grade 3 Significance 
MMP-2 34.1 ± 29.2 78.3 ± 39.1 159.0 ± 21.2 ns 
MMP-9  91.9 ± 10.3 187.2 ± 54.3 279.3 ± 23.2 P < 0.05 
MT1-MMP  45.3 ± 23.0 103.4 ± 25.2 183.3 ± 31.4 ns 
TIMP-2  182.4 ± 12.2 143.2 ± 17.8 97.3 ± 10.3 P < 0.01 
VEGF-A  106.6 ± 9.6 201.3 ± 15.5 291.3 ± 4.7 P < 0.001 
ns, not significant. 
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Fig. 3. Grade 3 MCT showing intense expression (multifocal to coalescing distribution) of MMP-2. IHC. X200. 
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Fig. 4. Grade 3 MCT showing intense and diffuse expression of MMP-9. IHC. X400. 
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Fig. 5. (a) MCT grade I showing negative labelling of neoplastic cells to MMP-2 (×400); (b) MCT grade II 
showing moderate and multifocal expression of MMP-2 (×200); (c) MCT grade I showing weak expression in 
rare neoplastic mast cells of MMP-9 (×400); (d) MCT grade II showing intense and diffuse expression of 
TIMP-2 (×200); (e) MCT grade III showing negative mast cells immunolabelled for TIMP-2 (×400); (f) MCT 
grade I showing negative mast cells immunolabelled for VEGFR-2 (×400); (g) MCT grade II showing 
immunohistochemical labelling of neoplastic cells for VEGF (×400); (h) MCT grade I showing scattered 
immunohistochemical labelling of neoplastic cells for VEGF antigen (×400). 
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Fig. 6. Grade 1 MCT showing intense and diffuse expression of TIMP-2. IHC. X200. 
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Fig. 7. Grade 3 MCT showing expression of VEGF antigen by tumour cells. IHC. X200. 
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Gelatin Zymography 
Active and inactive forms of MMP-9 and MMP-2 were measured by GZ (Fig. 8). The activities of 
MMP-9 and MMP-2 were calculated in a.u. per 10 ng of protein. The pro-MMP-9 band was 
present in all samples examined by GZ. The activity range in grade 1 tumours was 2.3 - 60.2 a.u., in 
grade 2 tumours 71.0 - 134.3 a.u. and in grade 3 MCTs 151.2 - 218.9 a.u. Thirty-four tumours 
exhibited bands for the active form of MMP-9. The activity ranged from 0 to 40.3 a.u. for grade 1, 
54.3 - 192.6 a.u. for grade 2 and 160.3 - 248.0 a.u. for grade 3 tumours. Pro- and active-MMP-9 
activities progressively increased from grade 1 to 3 MCTs. Both were higher in grade 3 than in 
grade 2 (p < 0.05), in grade 3 than in grade 1 (p < 0.001) and in grade 2 than in grade 1 tumours (p 
< 0.01; Fig. 7B). Furthermore, the activity of the MMP-9 latent form was significantly higher than 
the active form (p < 0.05) in grade 2 and 3 MCTs. Densitometric values of the active form of MMP-
9 were also correlated to MMP-9 mRNA expression (r = 0.37, p < 0.05). Bands for the latent and 
active forms of MMP-2 were found in 97% and 94% of MCTs, respectively. A progressive increase 
in MMP-2 gelatinolytic activity with histological grade was observed. The activity of pro-MMP-2 
was 0-31.4 a.u., 28.7-164.0 a.u. and 65.3-149.7 a.u. in grade 1, 2 and 3 tumours, respectively. The 
activity of MMP-2 was 0-23.9 a.u., 13.2-169.7 a.u. and 70.8-161.2 a.u. in grade 1, 2 and 3 MCTs, 
respectively. Significant differences were obtained for pro-MMP-2 in grade 1 versus grade 2 and in 
grade 1 versus grade 3 (p < 0.001) and for active-MMP-2 in grade 1 versus grade 2 (p < 0.01) and in 
grade 1 versus grade 3 (p < 0.001) (Fig. 8C). Pro-MMP-2 activity was significantly higher than 
active-MMP-2 only in grade 1 samples (p < 0.05). 
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Fig. 8. (A) Zymographic assay of gelatinase activity in grade 1, 2 and 3 MCTs and in HT1080 fibrosarcoma 
cells (CTRL). Bands corresponding to both latent (pro-) and active (act-) forms of MMP-9 and MMP-2 were 
observed in MCTs. HT1080 fibrosarcoma cells were used as the control for pro-MMP-9, pro-MMP-2 and 
act-MMP-2. (B and C) Densitometric analysis of the bands corresponding to latent and active forms 
ofMMP-9 (B) andMMP-2 (C) in grade 1, 2 and 3 MCTs. Integrated density values for each group (mean _ 
standard deviation) are expressed as a.u. as a percentage of the density recorded in CTRL (100 a.u.). a, b, c 
Significant differences between grade 1 and 2, grade 1 and 3 and grade 2 and 3, respectively (Kruskal-Wallis 
test followed by Dunn’s post test; c: p< 0.05; aa: p < 0.01; aaa, bbb: p < 0.001). 
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DISCUSSION 
Dogs are at risk for cutaneous MCT, which accounts for up to 21% of all skin tumours (Thamm and 
Vail, 2007). The diagnosis of MCT by cytology or histopathology is straightforward in the majority 
of cases, but forming an accurate prognosis is more challenging (Welle et al., 2008). The biological 
behaviour of MCT is highly variable, in particular for intermediate-grade tumours. Some 
intermediate-grade tumours have a benign behaviour, while others exhibit aggressive growth and 
a high frequency of local and distant recurrence (Welle et al., 2008). Degradation of the ECM and 
basement membrane components and angiogenesis act in a coordinated manner in the growth 
and progression of several human and animal tumours (Loukopoulos et al., 2003; Patruno et al., 
2009). These complex processes are mainly regulated by MMPs and their specific inhibitors (ECM 
and basement membrane degradation) and VEGF (angiogenesis). Few data are available on the 
roles of MMPs and VEGF-A in canine MCTs (Leibman et al., 2000; Loukopoulos et al., 2003; 
Patruno et al., 2009; Mederle et al., 2010). In veterinary oncology, this is the first study describing 
the expression of MMP-2, MMP-9, MT1-MMP, TIMP-2 and VEGF-A in canine MCTs using an 
integrated approach from mRNA to protein, by means of both qPCR and IHC. GZ was also 
performed to evaluate MMP-2 and MMP-9 gelatinolytic activity. MMP-2 and MMP-9 have been 
identified by GZ in 24 cases of canine MCT of histological grades 2 and 3 (Leibman et al., 2000) and 
in two cases of oral multifocal MCT by GZ and IHC (Loukopoulos et al., 2003). In those studies, 
normal tissue adjacent to the tumour was also considered. In the present study the activity of 
both latent and active forms of MMP-9 and MMP-2 was evaluated in grade 1, 2 and 3 MCTs and 
these data were compared with IHC and qPCR results. Both latent and active forms of MMP-9 and 
MMP-2 were found in almost all tumours and proenzyme activity was generally higher than the 
active form for both gelatinases. GZ showed a significant increase of the pro- and active forms of 
MMP-9 and MMP-2, correlated with histological grade, as previously observed by Leibman et al. 
(2000) in canine MCT and by Loukopoulos et al. (2003) in other tumour types. In general, the 
production of gelatinases is correlated with its biological behaviour: tumours produce more MMP-
9 and MMP-2 than non-neoplastic tissue and malignant tumours produce significantly more MMP 
than their benign counterparts (Loukopoulos et al., 2003). The grade dependent expression 
observed through zymography was confirmed at the mRNA and protein levels. Increased MMP-9 
mRNA expression was correlated with IHC score and with act-MMP-9 optical density by GZ. In 
contrast, MMP-2 expression was more variable: despite a grade-dependent increase in MMP-2 
activity. Multifocal distribution of the immunohistochemical expression was observed and there 
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were no significant differences between grades in terms of percentage labelled cells or intensity of 
labelling. Moreover, there was high variability at the gene expression level for MMP-2. The results 
obtained here for MMP-2 are in contrast with previously published data. The invasion and 
malignant potential of many canine solid tumours (e.g. lymphoma, mammary tumours and 
oronasal tumours) have been associated with increased expression of MMP-2 (Hirayama et al., 
2002; Papparella et al., 2002; Loukopoulos et al., 2003; Gentilini et al., 2005; Nakaichi et al., 2007; 
Aresu et al., 2011), while a minor role for MMP-9 in these tumours has been hypothesized 
because of its wide expression in normal cells, including macrophages and vascular smooth muscle 
cells (Nakaichi et al., 2007) or for the fact that the active form of MMP-9 was identified in only 
three cases among 51 tumours (Loukopoulos et al., 2003). In contrast, the results of the present 
study might suggest that MMP-9, rather than MMP-2, represents the key factor in ECM 
degradation by mast cells in canine MCTs and consequently in tumour aggressiveness and 
malignancy. MT1-MMP is one of the main activators of MMP-2. Mature active MT1-MMP is 
expressed on the cell surface, where it binds and activates pro-MMP-2 (Sato et al., 1994). 
Overexpression of MT1-MMP in tumour cells enhances human tumour growth and metastasis 
(Souliè et al., 2005). In veterinary oncology, MT1-MMP has been detected by IHC in canine 
mammary tumours, where its expression was observed in the cytoplasm of tumour and stromal 
cells (Papparella et al., 2002; Aresu et al., 2011). Both studies revealed increased expression of 
MT1-MMP in association with MMP-2 in canine mammary carcinomas and emphasised the 
contribution of stromal cells to the development of a pro-invasive micro-environment (Papparella 
et al., 2002; Aresu et al., 2011). In the present study, MT1-MMP mirrored MMP-2 behaviour at 
both the protein and mRNA levels. MMP-2 and MT1-MMP were both detected by IHC 
predominantly in the cytoplasm of tumour cells, and they showed multifocal distribution that 
increased in terms of percentage of labelled cells and intensity score with histological grade. At 
the gene expression level, MT1-MMP showed the same pattern of expression of MMP-2 and was 
positively correlated with MMP-2 expression. Thus, these results confirm the relationship between 
these two proteins in ECM degradation (Will et al., 1996). The gelatinolytic function of MMPs is 
also controlled by TIMPs. In particular, TIMP-2 has dual function of inhibition/activation of MMP-2 
(Lambert et al., 2004). No reports are available of the role of TIMP-2 in canine MCT; this has been 
investigated only in canine mammary tumours (Kawai et al., 2006; Aresu et al., 2011). In the 
present study IHC and qPCR showed the lowest level of TIMP-2 expression in undifferentiated 
MCTs, which appears to be consistent with the primary MMP inhibitory role played by TIMPs 
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(Lambert et al., 2004). Imbalances in the activities of MMPs and TIMPs are involved in tumour 
progression (Liotta et al., 1991). MMP-2 mRNA increases with respect to TIMP-2 in more 
aggressive tumours (Onisto et al., 1995; Caenazzo et al., 1998; Nagel et al., 2004; Nakaichi et al., 
2007); thus, the ratio of enzyme:inhibitor mRNA has been proposed as an early indicator of 
aggressiveness (Caenazzo et al., 1998; Nakaichi et al., 2007). In line with previous literature, a 
progressive increase in the MMP-2:TIMP-2 mRNA ratio according to tumour grade and malignancy 
was obtained here. To exert MMP-inhibiting or MMP-activating functions, TIMP-2 binds preferably 
to MMP-2, while TIMP-1 binds to MMP-9 (Stetler-Stevenson et al., 1989; DeClerck et al., 1991). 
Based on this evidence, the mRNA expression profile of TIMP-1 was examined here, but no 
statistically significant differences were obtained (data not shown). Nevertheless, the disturbed 
balance between MMPs and TIMPs in MCTs, as evidenced by the MMP-2:TIMP-2 mRNA ratio, was 
also confirmed by the MMP-9:TIMP-1 mRNA ratio, where in more aggressive MCTs (grade 3) an 
imbalance of about fourfold versus grade 1 was obtained. Thus, the MMP-2:TIMP-2 and MMP-
9:TIMP-1 mRNA ratios might be useful for predicting the behaviour of MCTs. Angiogenesis is 
crucial for the development of solid tumours and it is known that tumour-associated vessels can 
supply oxygen and nutrients to tumour cells for several millimetres (Uchida et al., 2008). VEGF is a 
major regulator of angiogenesis and a potential autocrine growth factor for neoplastic cells (Kutet 
al., 2007). Recently, VEGF-A distribution has been evaluated in normal canine tissues (Uchida et 
al., 2008) and in canine mammary tumours, meningiomas, lymphomas and MCTs (Wolfesberger et 
al., 2007, 2008; Qiu et al., 2008; Matiasek et al., 2009; Millanta et al., 2010; Mederle et al., 2010). 
Several studies have demonstrated significant correlations between tumour grade and angiogenic 
factors and/or microvessel density in canine mammary gland tumours, basal cell tumours and 
squamous cell carcinomas (Maiolino et al., 2000; Restucci et al., 2002). Furthermore, 
intratumoural microvessel density has been evaluated in canine MCT and associated with tumour 
recurrence and mortality (Preziosi et al., 2004). For the first time, VEGF-A was measured in MCT 
samples by means of IHC and, by qPCR in the present study. Both methods confirmed that 
neoplastic mast cells constitutively expressed VEGF-A at both the mRNA and protein levels, as 
described by Rebuzzi et al. (2007). Additionally, increasing VEGF-A mRNA and protein expression 
according to histological grade was observed. A similar association was described by Patruno et al. 
(2009). The results obtained here might form the basis for development of new therapeutic 
strategies for canine MCT. For example, the use of an antiangiogenic compound in association 
with other chemotherapeutic agents might be beneficial in the management of non-resectable 
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grade 2 and 3 MCTs. As an example, tyrosine kinase inhibitors with both anti-angiogenic and direct 
anti-neoplastic activities (inhibition of c-KIT tyrosine kinase activity) might be employed. In this 
respect, surprisingly, transcriptional data obtained here for VEGF-A in grade 1, 2 and 3 MCTs were 
significantly correlated with c-KIT mRNA levels (data not shown). In conclusion, the results of the 
present study have shown the involvement of MMP-9 and VEGF-A in the progression and 
malignancy of canine MCT. These markers may be new novel therapeutic targets, but future 
studies should collect clinical outcome data to further understand the potential prognostic roles of 
these markers. 
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5. PHASE 3 
5.1. SECTION 1: VEGF and MMP-9: biomarkers for canine 
lymphoma* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Adapted with the permission of “Blackwell” from: Aresu L, Aricò A, Comazzi S, Gelain ME, Riondato F, 
Mortarino M, Morello E, Stefanello D, Castagnaro M. VEGF and MMP-9: biomarkers for canine lymphoma. 
Vet Comp Oncol. 2012 Apr 10. doi: 10.1111/j.1476-5829.2012.00328.x. © 2012 Blackwell Publishing Ltd. All 
rights reserved. 
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BACKGROUND 
In human and veterinary oncology, one area of major promise is the identification of molecular 
markers, which may predict response to chemotherapy and tumour relapse, thereby offering 
predictive information. It has been reported that canine non-Hodgkin’s lymphoma (cNHL) shows 
overlapping features with human non-Hodgkin’s lymphoma (hNHL), allowing for the formulation 
of a comparative classification system and for the consideration of the dog as a possible 
spontaneous model for this tumour (Vail and MacEwen, 2000; Breen and Modiano, 2008). 
Cytokines play an important role in the pathogenesis of hNHL, and elevated plasma or tissue 
cytokine levels contribute to its progression (Pedersen et al, 2005; Labidi et al., 2009). Cytokines 
exert their effects on neoplastic and reactive cells, providing growth advantages for tumour cells in 
either an autocrine or a paracrine fashion (Sporn and Todaro, 1980).  Angiogenesis plays a critical 
role in the initial development of cancer as well as in the metastatic spread. Previous studies have 
shown that angiogenesis is increased in canine lymphoma, by highlighting the higher micro-vessel 
density in neoplastic lymph nodes compared with the normal lymph nodes (Wolfesberger et al., 
2008); however, the neovascularization was not correlated with VEGF immunoreactivity or overall 
survival time. Conversely, Gentilini et al. (2005) measured circulating VEGF, MMP-9 and MMP-2 in 
cNHL and found a longer disease-free interval in dogs with a low VEGF plasma level at admission; 
however, no differences in VEGF levels were noticed before and after treatment in eight dogs 
obtaining complete remission. When the included dogs were grouped according to some of the 
known prognostic factors, a significantly higher VEGF level was found in symptomatic dogs 
(substage b) compared with asymptomatic dogs (substage a). However, no attempt was made to 
evaluate the relationship between the level of angiogenic factors in cNHL and immunophenotype, 
cytological subtypes or grading. Moreover, activation of MMP-9 and MMP-2 was not evaluated. 
AIM 
By hypothesizing a relationship among cytokines and gelatinases, the aim of this work is the 
measurement of plasmatic pro-MMP-2, pro-MMP-9 and their activated forms, VEGF and TGF-β by 
gelatine zymography and an enzyme-linked immunosorbent assay, respectively, in a cohort of 
cNHL subdivided based on cytological classification and immunophenotype. Additionally, in a 
smaller group of dogs undergoing treatment, biomarkers levels at presentation will be correlated 
to clinical stage (to evaluate whether higher levels predicted a more advanced clinical stage), to 
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immunophenotype (B versus T) and to remission status at the end of chemotherapy (to evaluate 
whether variation in the angiogenic pathway may be related to remission status). 
 
METHODS 
Patients and samples 
Plasma was obtained from dogs with lymphoma at various clinical stages, and from breed-, age 
and gender-matched healthy control dogs presenting for periodical examination. An informed 
consent was obtained from all owners according to the regulations of each institutional animal 
care committee. Dogs underwent complete staging work-up, including physical examination, 
complete blood cell count, flow cytometric and cytological analysis of nodal fine-needle aspirate, 
peripheral blood and bone marrow aspirate, thoracic radiography and abdominal ultrasound. 
Briefly, flow cytometric immunophenotype was determined as previously reported on fine needle 
aspiration of lymph nodes, peripheral blood and bone marrow samples (Gelain et al., 2008). The 
following monoclonal antibodies were used: CD45-PEb (clone YKIX716.13, Serotec, Oxford, UK), 
CD3-FITC (clone CA17.2A12, Serotec, T cells), CD4-FITC (clone YKIX302.9, Serotec, T-helper and 
neutrophils), CD8-PE (clone YCATE55.9, Serotec, T-cytotoxic/suppressor), CD5 (clone YKIX322.3, T-
cell), CD21-PE (clone CA21D6 Serotec, mature B cells), CD34-PE (clone 1H6, Pharmingen, Becton 
Dickinson, San Jose, CA, USA, precursor cells), and CD79a (B-cells, clone HM57, Dako, Atlanta, GA, 
USA). Acquisition was performed with FACSCalibur (Becton Dickinson) and analysis was conducted 
by using a commercially available software (Cell Quest, Becton Dickinson). Lymphoma subtypes 
were classified based on the Kiel-updated cytological classification (Ponce et al., 2010). Plasma was 
processed by the Department of Veterinary Pathology, Hygiene and Health, University of Milan, 
and by the Department of Animal Pathology, University of Turin. At presentation, peripheral blood 
was sampled in sterile EDTA tubes, and the plasma obtained by centrifugation was put in 
separated polypropylene tubes and stored at −20°C. Each sample was centrifuged for 30 min at 
1000 rpm before assaying. Owners of dogs with lymphoma were offered to treat their animals 
with multidrug chemotherapy, consisting of doxorubicin, vincristine, cyclophosphamide, L-
asparaginase and prednisone (Simon et al., 2006). In these dogs, plasma was collected at three 
standard times (at diagnosis, halfway through the treatment and at the end of chemotherapy). 
The remission status of the treated dogs was recorded at each recheck examination. 
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MMPs analysis using gelatine zymography 
MMP-2 and MMP-9 activity was studied by zymography, a technique revealing the gelatinase 
activity of latent pro-enzymes (zymogens) and mature MMPs. A 1:10 dilution was made from 10 
μL of plasma into sample buffer, and 60 μL of the diluted sample was subjected to electrophoresis 
on an 8% SDS-PAGE gel co-polymerized with 0.1% gelatine. Other details about gelatine 
zymography are described in Phase 1.  
Measurements of cytokine levels 
Circulating VEGF and TGF-β levels were quantitatively analysed by an enzyme-linked 
immunosorbent assay (ELISA), using specific canine commercial kits (R&D Systems, Minneapolis, 
MN, USA) following manufacture instruction. Each sample was tested in duplicate. 
Spectrophotometer readings at 450nm (wavelength correction set to 570 nm) were performed 
using a Thermo Labsystems Multiskan Ascent Photometric plate reader (American Instrument 
Exchange, Haverhill, MA, USA). The lower limits of detection for VEGF and TGF-β1 are less than 
19.5 and 4.61 pg/mL, respectively. Samples were prepared with HCl/NaOH/HEPES-activation 
solution, as recommended by the manufacturer (R&D Systems), to activate latent TGF-β1 into the 
immunoreactive form, the only one detectable by the kit. 
Statistical analysis 
The data were expressed as the mean±SEM. Comparison among cytokines and MMPs levels in 
dogs with different lymphoma subtypes and healthy controls was calculated by Student’s t-test or 
analysis of variance (ANOVA). Differences in frequencies among all the cytokines were determined 
by χ2 analysis. Standard regression analysis, using Pearson and Spearman correlation coefficients, 
were used to determine the relationships between MMP, VEGF and TGF-β1 values. All tests were 
performed using NCSS 2000 software (Kaysville, UT, USA). Statistical significance was set at p<0.05. 
 
RESULTS 
Thirty-seven dogs with lymphoma and 10 healthy controls were evaluated. Among the lymphoma 
cases, 21 were of B-cell immunophenotype (19 high-grade, 1 low-grade and in 1 case no lymph 
node glass smear was available) and 16 of T-cell immunophenotype (9 high-grade and 7 low 
grade). The main B-cell subtype was centroblastic polymorphic (17 of 21), whereas in T-cell 
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lymphoma (including high- and low-grade) no predominant cytological subtype was detected. 
Thirty-four dogs underwent complete staging work-up: 20 lymphomas were of stages III–IV, 
whereas 14 of stage V. Twenty-nine of the 37 dogs were treated and received the same CHOP-
based chemotherapeutic protocol (Gelain et al., 2008). At the end of the 12 weeks of treatment, 
12 (41.4%) dogs were in complete remission, 3 (10.3%) obtained partial remission, 3 (10.3%) dogs 
had stable disease and 11 (38.0%) dogs experienced progressive disease. When considering 
immunophenotype and outcome, among the 18 treated dogs with B-cell lymphoma, 9 obtained 
complete remission, 2 partial remission, 2 stable disease and 5 experienced progressive disease. 
Among the 11 treated dogs with T-cell lymphoma, three obtained complete remission, one partial 
remission, one stable disease and six experienced progressive disease. 
Correlation between MMPs and cytokines profiles at admission and disease status, clinical stage 
and immunophenotype.  
The quantification of gelatinases through gel zymography showed similar values of pro-MMP-9 in 
tumour and control dogs (B-cell lymphomas = 93.1 ± 6.4 a.u.; T-cell lymphomas = 97.9 ± 9.4 a.u. 
and control dogs = 92.3 ± 2.5 a.u.). However, dogs with lymphoma showed a significantly higher 
catalytic activity of MMP-9 (p<0.01) compared with healthy controls (91.7 ± 4.8 a.u. versus 12.4 ± 
2.1 a.u., respectively; Table 1). When considering the cytokine levels and clinical stage, statistically 
significant higher expression of act-MMP-9 was found in stage V B-cell lymphomas (95.3 ± 3.4 a.u.) 
than in stage III/IV B-cell lymphomas (83.4 ± 4.7 a.u.; p<0.01). Higher expression of act-MMP-9 was 
found in stage V T-cell lymphomas (113.7 ± 3.2 a.u.) than in stage III/IV T-cell lymphomas (94.7 ± 
2.1 a.u.; p<0.05). When examining the immunophenotype, T-cell lymphomas presented a higher 
concentration of act-MMP-9 at the time of diagnosis (103.3 ± 2.9 a.u.) than B-cell lymphomas 
(89.2 ± 8.8 a.u.), and this was statistically significant (p<0.05). Neither lymphoma nor control dogs 
showed expression of act-MMP-2. Plasma levels of pro-MMP-2 were not significantly increased in 
lymphoma dogs (104.3 ± 10.2 a.u.) with respect to control dogs (98.2 ± 3.9 a.u.; Fig. 1; Table 1). 
Plasma VEGF levels in dogs with lymphoma were higher than that in controls (59.3 ± 14.3 pg/mL 
versus 40.1 ± 10.4 pg/mL, respectively; P<0.05), and this was statistically significant (P<0.05; Table 
1). Also, VEGF plasmatic levels were significantly higher (p<0.01) in stage V B-cell lymphomas (58.3 
± 4.5 pg/mL) than in stage III/IV B-cell lymphomas (49.1 ± 2.1 pg/mL), and in stage V T-cell 
lymphomas (78.1 ± 3.7 pg/mL) than in stage III/IV T-cell lymphomas (63.1 ± 4.5 pg/mL). In dogs 
with B-cell lymphoma, the mean VEGF value at diagnosis was lower when compared with dogs 
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with T-cell lymphoma (55.4 ± 21.3 pg/mL versus 67.4 ± 19.1 pg/mL, respectively). A positive 
correlation between concentrations of act-MMP-9 and VEGF plasma levels was found in all 
lymphoma dogs (r = 0.78, p<0.001). Concerning plasma TGF-β levels, the median values were 
similar between B- and T-cell lymphoma (11377.6 pg/mL and 10343.4 pg/mL, respectively). 
Although not statistically significant, the mean plasma TGF-β value in control healthy dogs 
(19185.5 pg/mL) was higher when compared with lymphoma dogs (Table 1). At the time of 
diagnosis, VEGF levels were significantly lower in low-grade (59.7 ± 3.3) compared with high-grade 
(76.4 ± 4.8) T-cell lymphomas (p<0.05). No such differences were observed for MMP-2, MMP-9 
and TGF-β. 
Correlation between MMPs analysis and cytokines profiles at admission and remission status at 
the end of chemotherapy.  
Plasma was obtained at admission in 29 dogs undergoing the same chemotherapeutic protocol. 
MMP and cytokines profiles did not differ between dogs obtaining remission (complete and 
partial) or experiencing progressive disease, thereby not being useful in predicting treatment 
response. 
MMPs analysis and cytokines profiles during chemotherapy and follow-up.  
Plasma was serially obtained from 13 dogs (10 B-cell and 3 T-cell lymphomas) undergoing 
chemotherapy. In these dogs, pro-MMP-9, pro-MMP-2 and act-MMP-2 levels did not change at 
the three standard times. However, act-MMP-9 was significantly decreased in all B-cell lymphoma 
dogs at the end of chemotherapy (38.1 ± 12.3 a.u.; p<0.01; Fig. 3). In contrast, no evident 
modifications of the quantitative activity of act-MMP-9 were observed in the T-cell lymphoma 
dogs (101.3 ± 10.0 a.u.; Fig. 2 and Fig. 3). In dogs undergoing chemotherapy, 8 of 9 cases of B-cell 
lymphoma showed decreased VEGF values at the end of treatment in the order of 19.47 pg/mL. 
The mean value of the reduction, excluding one case of anaplastic B-cell lymphoma that presented 
a rise of VEGF levels, was 20.7 pg/mL (p<0.05). In the three dogs with T-cell lymphoma undergoing 
treatment, the mean value of the rise of plasma VEGF was 15.6 pg/mL at the end of treatment. 
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Table 1. Baseline values of MMP-9 (pro and act), VEGF and TGF-β in controls, B-cell lymphomas 
and T-cell lymphomas (expressed as the mean ±SEM) 
 CONTROLS LYMPHOMA B LYMPHOMA T 
Pro-MMP9 (a.u.) 92.3 ± 2.5 93.1 ± 6.4 97.9 ± 9.4 
Act-MMP9 (a.u.) 12.4 ± 2.1 89.2 ± 8.8** 103.3 ± 2.9** 
VEGF (pg/ml) 40.1 ± 10.4 55.4 ± 21.4* 67.4 ± 19.1* 
TGF- β (pg/ml) 19185.5 ± 7843.4  11377.6 ± 3412.7   10343.4 ± 5430.9 
*p<0.05. **p <0.01 versus controls. 
 
 
 
Fig. 1. Representative MMP zymography from seven samples. Lanes 1, 2 and 3 are T-cell lymphomas. Lanes 
4, 5 and 6 are B-cell lymphomas. 
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Fig. 2. Representative MMP zymography from three dogs during chemotherapy. Lanes 1, 2 and 3: dog 6, B-
cell lymphoma, respectively, at time 2, time 1 and time 0. Lanes 4, 5 and 6: dog 17, B-cell lymphoma, 
respectively, at time 2, time 1 and time 0 in. Lane 7: T-cell lymphoma in dog 35. 
 
Fig. 3. Plasma concentrations of act-MMP-9 (mean values) in B- and T-cell lymphomas at the three standard 
times during the chemotherapy protocol. 
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DISCUSSION 
Cytokines act as important key regulators of the tumour microenvironment, by influencing survival 
and proliferation of neoplastic and vascular cells. In people with NHL, angiogenic factors are 
emerging as a powerful prognostic tool (Baly et al., 1993; Pedersen et al, 2005; Labidi et al., 2009). 
In literature, few studies are available in veterinary oncology on the role of VEGF and MMPs 
(Hirayama et al., 2002; Gentilini et al., 2005; Yonemaru et al., 2006; Zizzo et al., 2010; Aresu et al., 
2011) and the clinical impact of early and serial monitoring of these cytokines has not been 
extensively studied. Here, possible plasma biomarkers were identified having predictive relevance 
in canine lymphoma. Specifically, the results of present study show that VEGF and act-MMP-9 
levels were significantly higher (1) in dogs with lymphoma when compared with controls, (2) in T-
cell lymphomas compared with B-cell lymphoma at admission and that (3) VEGF was higher in 
high-grade compared with low grade T-cell lymphoma. MMP-9 and VEGF are two of the most 
potent factors involved in angiogenesis. It is well known that, in addition to its role in proteolytic 
degradation, MMP-9 can also release angiogenic factors that bind to ECM, such as VEGF. MMP-9 is 
also a functional component of the angiogenic switch during multistage carcinogenesis, as it 
increases the availability of angiogenesis inducers (Bergers et al., 2000; Moehler et al., 2003). In 
this study, a correlation between the levels of VEGF and act-MMP-9 and lymphoma 
immunophenotype was found; the explanation of which could rely on the more aggressive 
biological behaviour and rapid spread that characterize T-cell lymphoma. Indeed, it has been 
documented that canine T-cell lymphoma usually harbours a poor prognosis (Ponce et al., 2004): 
in the early stage, high-grade nodal lymphoma does not destroy tissue boundaries, thereby not 
showing an invasive growth pattern. However, as the tumour progresses, it may become locally 
invasive and tends to disseminate, as partially shown by predictive correlations exhibited in the 
present study between plasma levels of VEGF and MMP-9. However, it is a matter of fact that 
canine lymphoma encompasses a wide range of distinct entities showing different biologic 
behaviour; as a consequence, not all T-cell lymphomas carry the same prognosis (Ponce et al., 
2010). For this reason it was decided to group the cases based on their morphological aspect as 
well, and, interestingly, the low-grade T-cell lymphomas had a significant lower level of VEGF, 
being in accordance with results obtained in human medicine (Salven et al., 1997). On the basis of 
these findings it may be hypothesized that a different angiogenic pathway occurs in low- and high-
grade T-cell lymphomas. Because B-cell lymphomas were mainly of high-grade in the series 
considered in this study, it was not possible to discriminate the VEGF data. In hNHL, VEGF and 
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MMP-9 expressions correlate with: (1) subtype, (2) grade, (3) clinical course and (4) survival 
(Salven et al., 1997; Sakata et al., 2004). Patients with elevated VEGF and MMP-9 levels have a 
higher likelihood of recurrence or death than patients with low-angiogenic NHL. The role of VEGF 
and act-MMP9 in different stages of lymphoma (III–IV versus V) was analysed. Their levels were 
found to be different between lower and higher stages, thereby suggesting a possible role of 
cytokine levels to differentiate between advanced and early cancer. According to the results of the 
present, cytokines levels at presentation did not correlate to remission status obtained at the end 
of chemotherapy. The reason behind this finding may reside in the low number of treated cases or 
in distinct characteristics of the dog groups studied. It may be possible that group stratification 
according to clinical stage and immunophenotype will eventually lead to outcome correlation. 
Intriguingly, by serially determining cytokines level during and after chemotherapy, plasma VEGF 
and MMP-9 was recognized as a dynamic follow-up parameter in B-cell lymphoma. Indeed, both 
biomarkers decreased significantly from admission to the end of treatment in these dogs, thereby 
being in agreement with several human studies indicating that VEGF and MMP-9 might predict 
treatment response (Sakata et al., 2004; Pedersen et al, 2005; Labidi et al., 2009). At midterm 
plasma check, the biomarkers levels were not significantly different when compared with the 
levels obtained at admission (data not shown). As a consequence, it may be assumed that the 
most relevant changes in the production of these markers are reflected at the end of treatment, 
being attributable to the persistence of high circulating levels of VEGF and MMP-9 during 
chemotherapy. Conversely, in T-cell lymphomas, VEGF levels increased at the end of the 
treatment, whereas MMP-9 showed no changes. More data are needed to evaluate the plasma 
kinetics of these two biomarkers in dogs with lymphoma to predict a possible correlation between 
their synthesis and the responses to chemotherapy. On the other hand, the role of MMP-2 seems 
to be irrelevant in the lymphoma microenvironment. Pro-MMP-2 levels in dogs with lymphoma 
were not significantly increased, regardless of the immunophenotype. TGF-β showed lower 
plasma levels in lymphoma dogs compared with controls; however, there was a high individual 
variability at diagnosis. Furthermore, no correlation between plasma TGF-β levels and lymphoma 
immunophenotype was found, and there was no correlation at the three standard treatment 
times. It may be hypothesized that a reduction of TGF-β reflects the ability of the tumour cells to 
acquire resistance to the anti-proliferative signals of TGF-β. In NHL and other haematological 
malignancies, the aberrant expressions of receptors (types I, II and III) and mutations in TGF-β 
signalling cascade have been described, demonstrating that cancer cells frequently acquire 
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resistance to the anti-proliferative signals of TGF-β (Dong and Blode, 2006). The same may hold 
true for dogs with lymphoma; however, additional studies with larger patient numbers are 
warranted to verify these observations. In conclusion, VEGF and act-MMP-9 levels were 
significantly higher in dogs with lymphoma compared with healthy controls. Furthermore, VEGF 
and act-MMP-9 levels were higher in T-cell lymphomas and in dogs with a more advanced disease, 
thereby providing a new tool that might help oncologists in predicting outcome. Future studies 
need to be conducted to highlight the potential role of anti-angiogenetic agents in the treatment 
of different subtypes of canine lymphoma. 
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5.2. SECTION 2: Matrix metalloproteinases and vascular endothelial 
growth factor expression in canine lymphoma§ 
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AIM 
The aim of the second study on the canine lymphoma was to assess the gene expression profiles 
of MMP-2, MMP-9, MT1-MMP, TIMP-1, TIMP-2, RECK and VEGF-A and the protein levels of MMP-
2, MMP-9 and VEGF-A in canine B and T-cell lymphoma. 
 
METHODS 
Caseload and classification 
Fine-needle aspirates (FNAs) of enlarged lymph nodes obtained from dogs with lymphoma were 
collected. Samples were sent by the referring veterinarians to the Department of Veterinary 
Pathology, Hygiene and Health at the University of Milan, and to the Department of Animal 
Pathology at the University of Turin for diagnostic purposes. The different  subtypes were 
described according to the updated Kiel classification (Fournel-Fleury et al., 1997) by considering 
pleomorphism; cell size; nuclear shape; chromatin density; mitotic index; the number, size and 
distribution of nucleoli; and the extension and basophilia of the cytoplasm. The 
immunophenotype was determined by means of flow cytometry with the use of the following 
monoclonal antibodies: CD45-PEb (clone YKIX716.13, Serotec, Oxford, UK, leukocytes), CD3-FITC 
(clone CA17.2A12, Serotec, T cells), CD4-FITC (clone YKIX302.9, Serotec, T-helper cells and 
neutrophils), CD8-PE (clone YCATE55.9, Serotec, T-cytotoxic/suppressors), CD5 (clone YKIX322.3, 
T-cells), CD21-PE (clone CA21D6 Serotec, mature B cells), CD34-PE (clone 1H6, Pharmingen, Becton 
Dickinson, San Jose, CA, precursor cells), and CD79a (clone HM57, Dako, Atlanta, GA, all stages of 
B-cells). Data acquisition was performed by using a FACSCalibur (Becton Dickinson), and the 
analysis was conducted with a commercially available software (Cell Quest, Becton Dickinson). The 
expression of specific lineage markers defined the lineages of lymphoma: CD3, CD5, CD4, and/or 
CD8 for T-cell lymphoma and CD21 and/or CD79a for B-cell lymphoma. A positive staining referred 
to the antigen expression in at least 20% of the gated cells. Samples being characterized by an 
ambiguous diagnosis, low cellularity or viability were excluded from the present study. Five 
healthy dogs matched according to age, breed, and gender with no relevant peripheral lymph 
node alterations served as controls. Informed consent was obtained from all owners according to 
the regulations of each institutional animal care committee. 
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Sampling procedure 
Two samples were obtained from each lymph node FNA for routine cytological exam and flow 
cytometry, and for immunocytochemical analysis and total RNA extraction. For flow cytometry, 
cells were suspended in 0.5 mL of RPMI 1640 medium (Sigma Aldrich, Munich, Germany) 
containing 5% foetal bovine serum (Sigma Aldrich) and 0.2% sodium azide (Sigma Aldrich) at room 
temperature. The remaining material was washed twice in the same medium, re-suspended in 
RNAlater
®
 solution (Life Technologies, Foster City, CA) and stored at −20°C for total RNA isolation. 
For total RNA isolation, at least 0.5 mL of each cell suspension containing of 2 × 10
6
 cell/mL of 
good viability was required. 
Quantitative real-time RT-PCR (qRT-PCR) 
The total RNA was isolated using the RNeasy Mini Kit (Qiagen, Milan, Italy); according to the 
manufacturer’s instructions. RNA was isolated from both cell pellets and RNAlater
®
 suspensions, as 
recommended by Dunmire et al. (2002). To avoid genomic DNA contamination, on-column DNase 
digestion with the RNase-Free DNase set was performed. cDNA synthesis, primers and the 
formulation of final value are reported in Phase 1. Primer pairs and human UPL probes for MMP-2, 
MMP-9, MT1-MMP, TIMP-1, TIMP-2, RECK and VEGF-A amplification were described previously 
(Aresu et al. 2011; Giantin et al. 2012). In the present study, VEGF-164, the VEGF-A splice variant 
markedly expressed in dogs and highly conserved among species (Usui et al., 2004) was also 
considered. Canine VEGF-164 was amplified using the primer pair 5′-CGT GCC CAC TGA GGA GTT-3′ 
(forward) and 5′-AAG GCC CAC AGG GAT TTT CT-3′ (reverse) and human UPL probe #9. Calibration 
curves using a 4-fold serial dilution of a cDNA pool revealed PCR efficiencies near two and error 
values < 0.2 (see Table 1). 
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Table 1. qRT-PCR assay parameters: primer concentration, efficiency, linearity and dynamic range. 
Genes Primer concentration (nM) Efficiency Error Dynamic range (Cp) 
CGI-119 F600/R300 1.902 0.00291 23.90 – 32.39 
MMP-2 F600/R600 2.002 0.03450 25.57 – 32.68 
MMP-9 F300/R300 1.998 0.05740 30.50 – 36.28 
MT1-MMP F600/R600 2.001 0.02890 24.64 – 31.68 
TIMP-1 F600/R300 2.000 0.03110 25.24 – 31.25 
TIMP-2 F300/R300 2.034 0.02890 24.50 – 31.38 
RECK F600/R300 2.010 0.06310 27.05 – 33.78 
VEGF-A F300/R300 2.028 0.01020 26.56 – 32.49 
VEGF-164 F300/R300 1.998 0.02690 28.54 – 35.19 
F, forward primer; R, reverse primer 
 
Immunocytochemical analysis 
The protein expression levels of MMP-2, MMP-9 and VEGF-A were evaluated by 
immunocytochemistry. The cellular suspension designated for immunocytochemical analysis was 
prepared by cytospin and fixed with acetone and methanol (Sigma Aldrich). After fixation, the 
primary antibody incubation step was performed by an automated system for all antibodies 
(Ventana Medical Systems). The antibodies used in this study were the following: anti-human 
MMP-9, Clone C-TERM (1:200; Millipore S.p.A, Milan, Italy); anti-human MMP-2, Clone Ab-7 
(1:100; Thermo Fisher Scientific Inc., Kalamazoo, Michigan, USA); and anti-human VEGF-A, Clone 
A-20 – sc:152 (1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, California, USA). The details of 
the immunohistochemal performance and the labelling valuation are described in Phase 1.  
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Statistical analysis 
The statistical analysis of the gene expression results was performed using Mann–Whitney tests, 
whereas the immunocytochemistry data were analysed using the Kruskal-Wallis test followed by 
Dunn’s post-test. A non-parametric Spearman correlation analysis was used to determine the 
potential relationship between target genes. GraphPad Prism 5 software (San Diego, California, 
USA) was used for all statistical evaluations. Statistical significance was set at p<0.05. Finally, 
Grubbs’ test was used to identify potential outliers. 
 
RESULTS 
Clinical results 
Forty-seven dogs with lymphoma were enrolled. Based on cytological and flow cytometric 
evaluation, there were 26 B-cell lymphomas (22 high-grade, HG, and 4 low-grade, LG), and 21 T-
cell lymphomas (13 HG and 8 LG).  
qRT-PCR 
The gene expression results for healthy control lymph nodes, B-cell and T-cell lymphomas are 
summarised in Table 2. MMP-2 and TIMP-2 mRNA levels in the healthy control lymph nodes were 
significantly higher than in lymphomas. A significantly higher MMP-9 mRNA expression was 
observed in T-cell lymphomas compared to B-cell lymphomas and healthy controls. TIMP-1 
exhibited similar results to MMP-9: in particular, T-cell lymphomas exhibited significantly higher 
TIMP-1 mRNA expression than B-cell lymphomas and healthy controls. MT1-MMP displayed the 
opposite expression pattern of MMP-2 in T-cell lymphomas. Furthermore, significantly higher 
MT1-MMP expression was observed in T-cell lymphomas compared to B-cell lymphomas. MT1-
MMP mRNA levels were significantly higher in control lymph nodes than in B-cell lymphomas. 
When considering the tissue inhibitor RECK, statistically significant differences were observed 
between B-cell and T-cell lymphomas, and between T-cell lymphomas and healthy controls. B-cell 
and T-cell lymphomas had similar VEGF-A and VEGF-164 expression profile, moreover T-cell 
lymphomas showed significantly higher expression of VEGF-A with respect to controls. 
Interestingly, a higher MMP-9, MMP-2, MT1-MMP, VEGF-A, VEGF-164 and TIMP-1 mRNA 
expression was observed in HG T-cell lymphomas compared to LG T-cell lymphomas, although the 
differences were not statistically significant (Table 3). The same analysis was not performed in B-
cell lymphomas because of the low number of LG cases included in the study. The expression of 
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MMP-9, MT1-MMP, TIMP-1 and RECK was higher in HG T-cell lymphomas compared to HG B-cell 
lymphomas (p<0.05). Although not statistically significant, VEGF mRNA expression showed the 
same trend. Significant correlations between MMP-2 and TIMP-2 (p<0.001; Spearman r=0.82) and 
between MMP-9 and VEGF-A (p<0.01, Spearman r=0.67) were found in T-cell lymphomas. 
 
Table 2. MMP-9, MMP-2, MT1-MMP, TIMP-1, TIMP-2, VEGF-A, VEGF-164 and RECK mRNA 
expression in control lymph nodes, B-cell and T-cell lymphomas. 
Genes Control Lymph Nodes B-cell Lymphoma T-cell Lymphoma 
MMP-2 0.96 ± 0.23a,b 0.24 ± 0.28 0.16 ± 0.29 
TIMP-2 0.85 ± 0.34a,b 0.15 ± 0.20 0.16 ± 0.29 
MT1-MMP 0.61 ± 0.17a,b 0.11 ± 0.11c 0.94 ± 0.99 
MMP-9 0.13 ± 0.11b 0.12 ± 0.04 c 0.69 ± 0.11 
TIMP-1 0.15 ± 0.09b 0.16 ± 0.22 c 0.66 ± 0.75 
RECK 0.29 ± 0.12b 0.06 ± 0.12c 0.87 ± 1.12 
VEGF-A 0.37 ± 0.19b 0.71 ± 0.98 0.89 ± 1.37 
VEGF-164 0.57 ± 0.23 0.63 ± 0.92 0.90 ± 1.38 
Data are expressed as the mean ± standard error. 
a, b, c
 Significant differences between control lymph nodes and B-cell lymphoma, control lymph nodes and T-
cell lymphoma, B-cell lymphoma and T-cell lymphoma, respectively (Kruskal-Wallis test followed by Dunn’s 
post test; c: p < 0.05). 
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Table 3. MMP-9, MMP-2, MT1-MMP, TIMP-1, TIMP-2, VEGF-A, VEGF-164 and RECK mRNA 
expression in HG and LG T-cell lymphomas. 
Genes High grade Low grade 
MMP-2 0.18 ± 0.22 0.17 ± 0.20 
MMP-9 0.82 ± 0.15 0.12 ± 0.28  
MT1-MMP 1.01 ± 1.08 0.81 ± 0.86 
TIMP-1 1.07 ± 1.98 0.63 ± 0.92 
TIMP-2 0.15 ± 0.28  0.16 ± 0.32 
RECK 0.93 ± 1.26 1.67 ± 2.76 
VEGF-A 1.21 ± 1.65 0.35 ± 0.43 
VEGF-164 1.11 ± 0.92  0.39 ± 0.88 
Data are expressed as relative quantification values (mean ± SD) 
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Immunocytochemical analysis 
Immunocytochemical results are summarised in Table 4. The protein expression levels of MMP-9, 
MMP-2 and VEGF-A were significantly higher in T-cell lymphomas compared to B-cell lymphomas 
(Fig. 1, 2). A statistically significant difference between the healthy control FNAs and the 
lymphoma group (p<0.05) was also observed. Moreover, MMP-9 and VEGF protein expression was 
significantly correlated in B-cell lymphomas (p<0.0002; r=0.72) and T-cell lymphomas (p<0.006; 
r=0.69). 
 
Table 4. MMP-9, MMP-2 and VEGF-A protein expression in B-cell lymphoma and T-cell lymphoma. 
Target 
proteins 
Healthy control FNAs B-cell Lymphoma T-cell Lymphoma Significance 
MMP-9 0.57 ± 0.53 19.91 ± 28.99 68.13 ± 83.22 P<0.05 
MMP-2 0.14 ± 0.37 14.45 ± 22.50 15.64 ± 21.96 P<0.05 
VEGF-A 0.14 ± 0.37 6.4 ± 13.71 12.43 ± 17.88 P<0.05 
Data are expressed as immunostaining scores (mean ± SD) 
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Fig. 1. B-cell lymphoma. FNAs. (a) low number of positive immunoassayed lymphoid tumour cells for MMP-
2 antibody (arrow); (b) numerous positive immunoassayed lymphoid tumour cells for MMP-9 antibody 
(arrows); (c) plasma cells  and low percentage of immunoassayed lymphoid tumour cells for VEGF antibody 
(arrow). Immunocytochemistry, 400X. 
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Fig. 2. T-cell lymphoma. FNAs. intense and widespread positive immunoassayed lymphoid tumour cells for 
(a) MMP-2 antibody, (b) MMP-9 antibody and (c) VEGF antibody. Immunocytochemistry, 400X. 
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DISCUSSION 
In human haematologic malignancies, VEGF and different enzymes involved in ECM remodelling, 
including MMPs, are considered molecules for early diagnosis and prognostic assessment 
(Hayashibara et al., 2002; Pedersen et al., 2005; Buggins et al., 2011). The activation and 
inactivation of MMPs are regulated by TIMPs, which play a role in regulation of cell growth, and 
neovascularisation (Egeblad et al. 2002). In this study the expression of different MMPs, their 
regulators and VEGF, assessing mRNA and protein expression profiles, were analysed in canine 
lymphoma. Significantly higher MMP-9 mRNA and protein expression levels were observed in T-
cell lymphomas compared to B-cell lymphomas and healthy control lymph nodes, indicating that 
MMP-9 expression may be associated with tumour phenotype. Moreover, the difference was 
significantly higher in HG T-cell lymphomas compared with HG B-cell lymphomas. Biologically, T-
cells migrate across ECM barriers during the inflammatory process towards target tissues and the 
activation of MMP-9 causes the alteration of adjacent connective tissues and the degradation of 
collagen type IV. This result indicates that during tumour growth, neoplastic T-cells may increase 
the production of MMP-9, aimed at invading blood and other organs (Moehler et al., 2003). This 
data was confirmed by immunohistochemical results where T-cells expressed high amount of 
MMP-9 protein. Moreover, the gene and protein expression results for MMP-9 seem to confirm 
the prominent biologic behaviour of HG T-cell lymphoma characterized by invasion and metastatic 
spread, rendering this malignancy highly aggressive (Marconato et al., 2012). The highest levels of 
TIMP-1 were observed in T-cell lymphomas compared to B-cell lymphomas and controls. The 
highest levels were associated with HG T-cell lymphomas. This result supports the hypothesis that 
MMP-9 and TIMP-1 may act in concert in canine T-cell lymphoma. MMP-9 is frequently expressed 
and secreted with TIMP-1 by canine neoplastic cells (Aresu et al., 2011). These molecules are 
associated with a more aggressive clinical behaviour in human lymphomas, and they appear to 
exert their influence through two different mechanisms: MMP-9 causes ECM degradation, 
whereas TIMP-1 has an anti-apoptotic action (Kossakowska et al., 1991, and 1999). Furthermore, 
in human, increased TIMP-1 expression was observed in HG non-Hodgkin’s lymphomas and in 
advanced stage disease, leading the investigators to postulate that TIMP-1 may have lymphoid 
growth factor activity (Kossakowska et al., 1991). MMP-2 results were comparable to TIMP-2. 
Interestingly, in T-cell lymphomas, qRT-PCR analysis for MMP-2 revealed significant positive 
correlations with TIMP-2 and a negative correlation with MT1-MMP. By immunohistochemistry, 
neoplastic lymphocytes exhibited positive immunoreaction to MMP-2, confirming the protein 
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expression of this enzyme by neoplastic cells. Indeed, the MMP-2 antibody used in this work 
allows identifying both the inactive and active form of the enzyme. Gelatine zymography of T and 
B neoplastic cells was performed to investigate the activity of MMP-2 and MMP-9, but it was 
unable to detect any catalytic process. This discrepancy may be explained by the characteristics of 
the methodologies: immunocytochemistry shows the distribution and localisation of specific 
antigens within the cells, qRT-PCR can detect small quantities of transcripts in a relatively low 
number of cells, whereas gelatine zymography is sensitive to the number of cells preventing 
detection (Snoek-van Beurden and Von Der Hoff, 2005). Interestingly, higher MT1-MMP mRNA 
expression levels were observed in T-cell lymphomas compared to B-cell lymphomas and in HG T-
cell lymphomas with respect to the LG counterparts. This result supports the important role of 
MT1-MMP in tumour invasion and also to promote tumour angiogenesis, by degrading the fibrin 
matrix that surrounds newly formed vessels (Egeblad et al., 2002). In both T- and B-cell 
lymphomas, VEGF expression at the transcript and protein level was observed.  Tumour 
vascularisation is higher in lymphomas than in control lymph nodes and increases in HG T-cell 
lymphomas. VEGF is also present in lymphoma cells. Moreover, the mRNA and protein VEGF 
results were correlated with MMP-9 results in T-cell lymphomas. These data appear to be in 
accordance with the previous work of this project, where a close relationship between MMP-9 and 
VEGF plasmatic levels in canine lymphomas was reported (Aresu et al., 2012). The same results 
were observed in canine mast cell tumours, where release of VEGF by mast cells is correlated with 
higher MMP-9 production (Giantin et al., 2012). Indeed, the feedback regulation between MMP-9 
and VEGF is assumed to be implicated in the angiogenic switch.  In conclusion, the present data 
provides new information in the complex interaction of the migration/adhesion genes and canine 
lymphoma. Further efforts should be directed towards clarifying the detailed molecular 
mechanisms, including signal transduction and polymorphisms, which may lead to novel 
therapeutic strategies. The tumour vasculature is an attractive target for lymphoma therapy. The 
results from this study also indicate that differences between lymphoma subtypes must be taken 
into account in the selection of the most suitable dogs for trials with anti-angiogenic agents. 
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5.3. SECTION 3: Matrix metalloproteinases and vascular endothelial 
growth factor expression in canine leukaemias*§ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Adapted with the permission of “Elsevier” from: Aricò A, Giantin M, Gelain M, Riondato F, Mortarino M, 
Comazzi S, Dacasto M, Castagnaro M, Aresu L. Vet J. 2012 Nov 7. pii: S1090-0233(12)00426-1. doi: 
10.1016/j.tvjl.2012.10.004. © 2012 Elsevier Ltd. All rights reserved. 
§
 Presented at the 2012 World Veterinary Cancer Congress, Paris, France, March 1-2-3, 2012.  
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BACKGROUND 
Acute lymphoblastic leukaemia (ALL) is an uncommon but devastating disease in dogs; it is 
frequently and rapidly fatal (Adam et al., 2009). Conversely, chronic lymphocytic leukaemia (CLL) is 
an indolent disease affecting middle-aged to elderly dogs, it is often diagnosed incidentally and 
characterised by an indolent behaviour (Comazzi et al., 2011). Although canine acute and chronic 
leukaemias show different clinical behaviour and outcome, leukaemic cells proliferate abnormally, 
replacing normal bone marrow tissue and contributing to invasion of the extra-cellular matrix 
(ECM) and resulting blood involvement (Adam et al. 2009).  
AIM 
To better understand the pathogenesis of canine leukaemia, the present study assessed the 
expression profiles of the MMP-2, MMP-9, MT1-MMP, TIMP-1, TIMP-2, RECK and VEGF-A genes 
and the protein levels of MMP-2, MMP-9 and VEGF-A in canine leukaemia. 
 
METHODS 
Caseload and classification 
Peripheral blood samples were collected in EDTA-containing tubes from dogs with haematopoietic 
neoplasia and sent for diagnostic purposes by the referring veterinarians to the Department of 
Veterinary Pathology, Hygiene and Health at the University of Milan and to the Department of 
Animal Pathology at the University of Turin. Each blood sample was analysed using the Sysmex XT-
2000iV (Sysmex Corporation, Kobe, Japan). Peripheral blood and bone marrow smears, when 
available, were stained with May–Grunwald–Giemsa (Merck KGaA, Frankfurt, Germany) and used 
to obtain leukocyte differential counts and morphologic evaluations of the blast cells. To 
determine the immunophenotype, flow cytometric analyses were performed on the peripheral 
blood samples after erythroid lysis in 2 mL of erythrocyte lysis buffer (9% ammonium chloride, 1% 
potassium bicarbonate, 0.037% ethylenediaminetetraacetic acid (Sigma Aldrich, Munich, 
Germany)). The cells were suspended in RPMI 1640 medium (Sigma Aldrich, Munich, Germany) 
containing 5% foetal bovine serum and 0.2% sodium azide to a final concentration of 1 × 10
4
 
cells/µL, and 50 µL of the cell suspensions was used in each tube for the labelling procedures. The 
details of antibodies are reported in Phase 3 – Section 2. Clinical, clinicopathological and 
immunophenotypic data were used to classify leukaemia samples as previously described (Gelain 
et al, 2010). In particular, AL was diagnosed by the presence of: moderate to severe anaemia 
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and/or thrombocytopaenia, leukocyte morphology suggestive of immature or blast cells, more 
than 20% of blast cells in the bone marrow, CD34 positivity, and either CD3, CD5, CD4, and CD8 
positivity for T-cell ALL, or CD21 and CD79a positivity for B-cell ALL. Samples were classified as 
acute undifferentiated leukaemia (AUL) when the atypical cells expressed only CD34 and CD45. CLL 
was diagnosed by the presence of: severe lymphocytosis, monomorphic population of mature 
lymphocytes, negative serologic titre for Ehrlichia, Leishmania or any other identifiable cause of 
lymphocytosis, and either CD3, CD5, CD4 and CD8 positivity for T-cell CLL, or CD21 and CD79a 
positivity for B-cell CLL. Six peripheral blood samples for immunocytochemical analysis and four 
peripheral blood samples for quantitative real-time RT-PCR from healthy dogs matched according 
to age, breed and gender were used as controls. All samples were obtained during an annual 
general health visit, and informed consent was obtained from all owners. 
Sampling procedure  
Peripheral blood samples collected in EDTA tubes were firstly submitted to erythroid lysis with 2 
mL of erythrocyte lysis buffer. A portion of the sample was used for routine flow cytometric and 
immunocytochemical analyses, whereas the remainder was placed in polypropylene tubes with 10 
parts of RNAlater
®
 solution (Life Technologies, Foster City, CA) for total RNA isolation.  At least 0.5 
mL of each cell suspension containing of 2 × 10
6
 cell/mL with good viability was required for total 
RNA isolation.  To obtain pure lymphocytes from healthy controls, EDTA blood from the four 
healthy dogs was pooled. After red blood cells (RBCs) lysis, lymphocytes were separated through 
granulocytes+monocytes depletion, using MACS separation system. Briefly, after staining with 
anti-CD11b (clone CA16.3E10, Serotec) and anti-NSA monoclonal (clone CADO48A, VMRD Inc., 
WA) antibodies (both IgG1 isotype), pelleted leukocytes were magnetically labelled with anti-IgG1 
microbeads and passed through MS columns placed in the magnetic field (MACS separator), thus 
collecting the CD11b-negative NSA-negative fraction. Removing the column from the separator, 
the magnetical retained (CD11b+NSA+) fraction was eluted in a separate tube. Subsequently, 
purity (98%) and recovery (99%) of lymphocytes were determined by flow cytometric analysis (BD 
Accuri C6) as percentage of CD11b-negative cells in the unlabelled fraction and percentage of 
CD11-positive cells in the labelled fraction, respectively. 
Quantitative real-time RT-PCR (qRT-PCR) 
Total RNA isolation, cDNA synthesis, primers, calibration curve data and the formulation of final 
value are reported in Phase 3 – Section 2.  
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Immunocytochemical analysis 
The details of the immunohistochemal performance, the antibodies and the labelling valuation are 
described in Phase 3 – Section 2.  
Statistical analysis 
The statistical analysis of the gene expression results was performed using the Mann–Whitney 
test, whereas the immunocytochemistry data were analysed using the Kruskal-Wallis test followed 
by Dunn’s posttest. A non-parametric Spearman correlation analysis was used to determine 
potential relationships among target genes and between target genes and percentage of 
neoplastic cells. GraphPad Prism 5 software (San Diego, California, USA) was used for all statistical 
evaluations. Statistical significance was set at p<0.05. Finally, Grubbs’ test was used to identify 
potential outliers. 
 
RESULTS 
Clinical results 
Peripheral blood samples were obtained from 23 dogs.  According to the haematological and flow 
cytometric diagnosis, 11 dogs were classified as AL: 2 T-cell (CD34+CD5+), 2 B-cell (CD34+CD79a+) 
and 7 acute undifferentiated leukaemias (CD34+). Eleven dogs were females and one male, with a 
median age of 8 years (range, 2-12 years). All of the dogs were anaemic, thrombocytopenic 
associated with leucocytosis.  Twelve dogs where classified as T-CLL: 8 CD8+, 1 CD4+, 1 CD21+ and 
2 CD4-CD8-). Ten dogs were males and 2 females, with a median age of 10 years (range, 5-13 
years). All of the dogs showed leucocytosis and six of them were anaemic. The median percentage 
values (range) of neoplastic cells in blood were 98.1 (72-100) for AL and 88.2 (72-96) for CLL. 
qRT-PCR 
The gene expression results are summarised in Table 1 and 2. In lymphocyte control pool the 
mRNA expression of target genes was generally very low: MMP-2 mRNA was undetectable (n.d.); 
MMP-9, TIMP-2 and RECK mRNAs were detectable but not quantifiable (n.q.); MT1-MMP, TIMP-1, 
VEGF-A and VEGF-164 mRNAs were detectable and quantifiable. All selected genes were 
successfully amplified in ALL and CLL groups, with the exception of MMP-2.  All the genes were 
more expressed in AL and CLL than control lymphocytes (MT1-MMP only for AL), except for TIMP-
1 that showed a lower level of gene expression in pathological samples  compared with control 
lymphocytes and MMP-2 that was never amplifiable.  Although not statistically significant, the 
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mRNA levels of MMP-9, TIMP-1, RECK and VEGF-A were higher in CLL compared to AL cases. 
Instead TIMP-2 and MT1-MMP mRNA levels were significantly higher in AL than CLL. In CLL, 
significant positive correlations were found between MMP-9 and VEGF mRNAs (p<0.01; Spearman 
r = 0.7545) and between MMP-9 and TIMP-1 mRNAs (p<0.05, Spearman r = 0.6182). Moreover,  
the gene expression results were correlated with the percentage of neoplastic cells in the AL and 
CLL blood samples. Negative correlations were found between the percentage of neoplastic cells 
for MMP-9 mRNA (p<0.01; 95% confidence interval-CI- "-0.9259 to -0.2760"; Spearman r = -
0.7426), for VEGF mRNA (p<0.05, 95% CI "-0.8761 to -0.01326"; r = -0.5954), for TIMP-1 mRNA 
(p<0.05, 95% CI "-0.8836 to -0.04644"; r = -0.6165) and for TIMP-2 mRNA (p<0.05, 95% CI "-0.8970 
to -0.1107"; r = -0.6550). Furthermore, the percentage of neoplastic cells was negatively 
correlated with MMP-9 mRNA (p<0.05; 95% CI "-0.9188 to -0.1530"; r = -0.7002). 
 
Table 1.  MMP-9, MMP-2, TIMP-2 and RECK mRNA expression in AL and CLL 
Target Genes ALL CLL p values 
MMP-9 0.20 ± 0.19 0.59 ± 0.64 0.1891 
MMP-2 n.d. n.d. - 
TIMP-2 5.28 ± 3.94 0.51 ± 0.60 0.0043 
RECK 0.11 ± 0.12 0.23 ± 0.19 0.1611 
Data are expressed as relative quantification values; arbitrary units (mean ± SD) 
n.d. = not detectable  
Control lymphocytes = not quantifiable 
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Table 2. MT1-MMP, TIMP-1, VEGF-A and VEGF-164 mRNA expression in AL and CLL 
Target Genes ALL CLL p values 
MT1-MMP 1.20 ± 0.91 0.36 ± 0.48 0.0316 
TIMP-1 0.39 ± 0.25 0.77 ± 0.72 0.2485 
VEGF-A 2.55 ± 3.17 3.19 ± 3.57 0.8777 
VEGF-164 4.10 ± 5.05 4.07 ± 4.75 0.7818 
Data are expressed as fold changes; arbitrary units (mean ± SD) 
Control lymphocytes = 1 
 
 
Immunocytochemical analysis 
Immunocytochemical data for MMP-9, MMP-2 and VEGF-A are summarised in Table 3. The scores 
for all of the assessed proteins were higher in CLL than in AL (Fig. 1, 2); a significant difference was 
observed between the control peripheral blood and the leukaemia blood samples (p<0.05). 
 
Table 3. Immunostaining score values for MMP-9, MMP-2 and VEGF-A expressed as the mean 
(range)  
 Control peripheral blood AL CLL p values 
MMP-9 0.66 ± 0.51 78.11 ± 64.48 104.1 ± 36.8 0.0009 
MMP-2 0.16 ± 0.40 56 ± 53.5 71.73 ± 35.51 0.0008 
VEGF-A 0.5 ± 0.54 21.33 ± 23.62 27.9 ± 15.62 0.0008 
 
 
 
PHASE 3 - SECTION 3: MMPs and VEGF expression in canine leukaemias  Pag. 95 
 
Fig. 1. ALL. Peripheral blood. (a) plasma cells and lymphoid leukaemia cells brown immunostained for 
MMP-2 (arrow); (b) lymphoid leukaemia cells intensely immunostained for MMP-9 (arrow); and (c) VEGF 
(arrow). Immunocytochemistry, (bar = 70 lm). 
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Fig. 2. CLL. Peripheral blood. lymphoid leukaemia cells intensely and diffusely brown immunostained for (a) 
MMP-2 (arrow), (b) MMP-9 (arrow), and (c) VEGF (arrow). Immunocytochemistry, (bar = 70 lm). 
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DISCUSSION 
Angiogenesis and invasion play an essential role in tumour growth both in solid and hematopoietic 
tumours in humans (Moehler et al., 2003). Invasion and dissemination of neoplastic cells are 
regulated by several compounds, in particular MMPs and TIMPs. VEGF has also an influence in this 
contest and in tumoural neoangiogenesis (Hayashibara et al., 2002, Pedersen et al., 2005, Buggins 
et al., 2011). In veterinary medicine, different works report the role of these molecules in solid 
tumours, but there are no data for haematological malignancies. The aim of this study was to 
investigate different MMPs, their regulators and VEGF in canine acute and chronic leukaemias by 
assessing their mRNA and protein expression profiles. By definition, AL is the uncontrolled 
proliferation or expansion of haematopoietic cells that are arrested in an early stage of 
development. The excessive egress from the bone marrow into the peripheral blood is followed by 
the infiltration and by the failure of other tissues and organs (Adam et al., 2009). On the contrary, 
CLL is an indolent disease characterised by the accumulation in the bone marrow of long-lived cells 
of low proliferative rate, leading to progressive peripheral lymphocytosis (Seelig et al., 2010). In 
the present study, AL and CLL showed high MMP-9, VEGF-A and VEGF-164 mRNA levels and a 
positive correlation between MMP-9 and VEGF and between TIMP-1 and MMP-9 was 
demonstrated in CLL. All the target genes were also screened in pure lymphocytes obtained from 
healthy control donors. MMP-9 mRNA was not quantifiable and the protein was not expressed in 
control lymphocytes; whereas higher MMP-9 transcript and protein levels were present in CLL 
compared to AL. Different authors reported that MMP-9 is necessary for cellular mobility, 
transendothelial migration and basement membrane invasion by neoplastic cells (Ries et al., 1999, 
Redondo-Munoz et al., 2008). This may be valid in dog where CLL is characterized by the 
accumulation in the peripheral blood of neoplastic lymphocytes, which progressively infiltrate the 
bone marrow and secondary lymphoid tissues. VEGF was highly expressed at the mRNA and 
protein level in both AL and CLL in respect to control lymphocytes; furthermore, the values for this 
protein were higher in CLL compared to AL. The hypothesis is that VEGF elevated levels in 
leukaemic cells could stimulate the growth of new blood vessels in the angiogenetic process and 
subsequently increase the permeability of endothelium and the cell motility through the vessels 
leading to the dissemination of cells into organs (Letilovic et al., 2006). Several studies have also 
indicated that VEGF may promote tumour proliferation (Hayashibara et al., 2002; Poyer et al., 
2009; Gehrke et al., 2011). Moreover, a significant positive correlation between VEGF and MMP-9 
mRNA levels was demonstrated in CLL samples. It is already known that MMP-9 and VEGF are two 
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of the most potent factors involved in angiogenesis through different mechanisms. This result 
provides evidence of the role of MMP-9 in the regulation of neovascularisation in a sort of vicious 
circle with VEGF. At first, VEGF can stimulate MMP-9 secretion acting as an autocrine factor and 
subsequently MMP-9 can release different angiogenic factors that bind to ECM, such as VEGF 
(Bergers et al., 2002; Moehler et al., 2003). In human medicine, both proteins are correlated with 
the substage of the disease and the risk of progression in CLL; follow-up data were not complete 
and survival analysis was not performed in this study (Letilovic et al., 2006). TIMP-1 transcript was 
expressed in both AL and CLL, and a significant positive correlation between MMP-9 and TIMP-1 
levels was demonstrated in CLL. MMP-9 is frequently found to be co-expressed with TIMP-1 in 
canine solid tumours; the same mechanism in CLL was confirmed (Aresu et al., 2011). TIMP-1 is 
also associated with a more aggressive clinical behaviour in human leukaemias, acting as an anti-
apoptotic and differentiation-promoting factor (Kossakowska et al., 1991; Kossakowska et al., 
1999; Scrideli et al., 2010). Interestingly, TIMP-2 mRNA expression was no quantifiable in control 
lymphocytes, whereas the data was 5-fold higher in AL than in CLL. According to literature, TIMP-2 
plays several roles in tumourigenesis, and is associated with an unfavourable prognosis and 
tumour progression (Egeblad et al., 2002). In canine AL samples, TIMP-2 was one of the most 
highly expressed genes and this might be concordant with the well-known erythroid-potentiating 
activity and the stimulation of leukaemic cells and fibroblasts growth of this protein (Stetler-
Stevenson et al., 1992; Hayakawa et al., 1994; Corcoran et Stetler-Stevenson, 1995). 
Unfortunately, no data for TIMP-2 protein were available in this work but the negative correlation 
with MMP-2 observed demonstrate that the biological role of natural inhibitor of MMP-2 
proteolytic activity is still active. MT1-MMP transcript was significantly different between AL and 
CLL. MT1-MMP is usually localised on the cell surface, where it regulates different members of the 
MMPs family, such as pro-MMP-2 and pro-MMP-13, creating a wider proteolytic repertoire on the 
cell surface. In particular, the MMP-2 activity is regulated by the formation of a ternary complex 
that consists of the C-terminal domain of pro-MMP-2, TIMP-2 and MT1-MMP.  The comparable 
results for TIMP-2 and MT1-MMP suggest the presence of this mechanism in AL. However, MT1-
MMP alone can also degrade various ECM macromolecules, including collagen, fibronectin and 
laminin (Egeblad et al., 2002). Hotary et al. (2003) reported that the expression of MT1-MMP is 
crucial for cancer cell growth in a 3D collagen-based matrix, suggesting that MT1-MMP has an 
important role in cancer invasion. CLL, AL and control lymphocytes showed an undetectable level 
of MMP-2 mRNA. MMP-2 expression is rarely observed in human ALL (Kuittinen et al., 2001; 
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Scrideli et al., 2010). Paradoxically, MMP-2 protein expression was identified in leukaemic cells by 
immunocytochemical analysis but not in lymphocytes in control blood. This discrepancy can be 
explained by the fact that MMP-2 protein activity is mainly regulated at the post-transcriptional 
level (Brown et al., 1990). In different solid tumours it has been demonstrated the catalytic activity 
of MMP-2 with insignificant expression of MMP-2 mRNA (Caenazzo et al., 1998; Aresu et al., 
2011). Interestingly, an inverse correlation between the percentage of neoplastic cells and the 
expression of all the genes was identified in CLL. Similar result was obtained for MMP-9 in AL. The 
residual population (i.e. neutrophils and monocytes) might influence the expression levels of 
MMP-9, MT1-MMP, VEGF and TIMPs, proportionally. It's already known that neutrophils and 
monocytes are able to express physiologically different MMPs, it remains still not fully understood 
the participation of these cells in the tumour microenvironment (Letilovic et al., 2006). In 
conclusion, significant relationships were demonstrated between MMP-9 and VEGF and between 
MMP-9 and TIMP-1 in CLL. MMP-9, TIMP-1 and VEGF were highly expressed in CLL and TIMP-2 and 
MT1-MMP in AL. In this study a first evidence of the potential role of these molecules was 
provided in pathogenesis of canine leukaemia. Further studies are needed to clarify the detailed 
molecular mechanisms involved in the signal transduction of MMP-2, MT1-MMP and their specific 
regulators/inhibitors. Moreover, MMP-9 and VEGF could be further investigated in plasma during 
haematological malignancies in dogs and correlated to the clinical data. Understanding their roles 
may help in designing new therapeutic strategies for canine leukaemias.  
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5.4. SECTION 4: Expression of Matrix Metalloproteinases, Tissue 
Inhibitors of Metalloproteinases and Vascular Endothelial 
Growth Factor in Canine Lymphohematopoietic malignancies 
cell lines 
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BACKGROUND 
Several studies in human lymphohematopoietic malignancies were performed in vitro to elucidate 
the possible involvement of growth factors and proteinases without the confounding influence of 
stromal and endothelial cells found in lymphoma tissue specimens. MMPs have been investigated 
in human cell lines of B and T-cell origin (Kossakowska et al., 1999; Stetler-Stevenson et al., 1997). 
More recently VEGF and its receptors were detected in human cell lines of cutaneous T-cell 
lymphoproliferative disorders (Pedersen et al., 2012) and in precursor B-cell acute lymphoblastic 
leukaemia cell line (El-Obeid et al., 2004). To date, little is known about these molecules in canine 
tumour cell lines: in vitro MMPs were detected in canine melanoma (Docampo et al., 2011), 
macrophage/monocytic tumour (Puff et al., 2009) and osteosarcoma (Loukopoulos et al., 2004), 
whereas VEGF and its receptors in canine mastocytoma (Rebuzzi et al., 2007). 
AIM 
The aim of this study is to consider the expression of various MMPs and their inhibitors, VEGF and 
VEGFR-2 at both the mRNA and protein levels in four different canine lymphohematopoietic 
malignancies cell lines. These analyses were performed to elucidate the possible involvement of 
these molecules without the confounding influence of microenvironment in the pathogenesis of 
canine lymphoid neoplasms. 
 
METHODS 
Cell lines 
Canine cell lines used in this study include: B-cell lymphoma cell line CLBL-1 (Rütgen et a., 2010),T-
cell lymphoma cell line OSW (Kisseberth et al., 2007), T-lymphoblastoid cell line CL-1 (Momoi et 
al., 1997) and B-cell leukaemia cell line GL-1 (Nakaichi et al., 1996) (Fig. 1). The cell culture 
conditions were described previously by Rütgen et al. (2010). 
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Fig. 1. Canine lymphohematopoietic malignancies cell lines. A) B-cell lymphoma cell line CLBL-1. B) T-cell 
lymphoma cell line OSW. C) T-lymphoblastoid cell line CL-1. D) B-cell leukaemia cell line GL-1. 
(Haematoxylin-Eosin - 400X)  
 
Sampling procedure 
The cells were harvested at the exponential growth phase, washed 3× in RPMI 1640 medium 
(Sigma Aldrich, Munich, Germany) with serum (as an internal control – conditioned medium 
presents slight amounts of MMPs) or serum-free, aliquoted at a concentration of 2 × 10
6
cells/mL 
and incubated for 24 hours at 37°C and 5% CO2. The cell-conditioned media (supernatants) were 
collected to perform gelatin zymography, whereas two samples were obtained from each cell 
pellet for immunocytochemical analysis and total RNA extraction. For both protein and mRNA 
expression, at least 0.5 mL of each cell suspension containing of 2 × 10
6
 cell/mL of good viability 
was required. 
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Quantitative real-time RT-PCR (qRT-PCR) 
The total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. To avoid genomic DNA contamination, on-column DNase digestion 
with the RNase-Free DNase set was performed. cDNA syntheses were done using 250 ng RNA and 
the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany) following the manufacturer’s 
protocol. Primers, calibration curve data and the formulation of final value are reported in Phase 3 
– Section 2.  
Immunocytochemical analysis 
The protein expression levels of MMP-2, MMP-9, MT1-MMP, TIMP-2, VEGF-A and VEGFR-2 were 
evaluated by immunocytochemistry. The details of the immunohistochemal performance are 
described in Phase 3 – Section 2. The pertinent antibody details are summarized in Table 1. The 
intensity and the index of immunoassayed tumour cells were assessed for each antibody. 
Antibodies labelling index was defined as the percentage of tumour cells displaying 
immunoreactivity in ten randomly selected fields at 400x magnification. An intensity score of 0 
was given when no staining was detected, a score of 1 denoted moderate staining and a score of 2 
represented strong staining. The total score for each examined field was obtained by multiplying 
the intensity score by the index. A final ratio was obtained after averaging the ten selected fields. 
The image analysis system included an Olympus BX51 microscope and a software analysis 
(analySIS, Soft imaging system, Münster, Germany). 
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Table 1: Details of antibodies 
Antigen Source Clone Dilution Manufacturer 
MMP-9 Human C-TERM 1:200 Millipore S.p.A, Milan, Italy 
MMP-2 Human Ab-7 1:100 Thermo Fisher Scientific Inc., Kalamazoo, 
Michigan, USA 
TIMP-2 Human MAB 3310 1:500 Chemicon (Millipore) 
MT1-MMP Human AB8221 1:200 Chemicon (Millipore) 
VEGF-A Human A-20 – sc:152 1:100 Santa Cruz Biotechnology, Inc., Santa Cruz, 
California, USA 
VEGFR-2 Human Flk-1 (A-3): sc-6251 1:50 Santa Cruz Biotechnology, Inc., Santa Cruz, 
California, USA 
 
MMPs analysis using gelatine zymography 
MMP-2 and MMP-9 activity was studied by zymography. A 1:4 dilution was made from 
supernatants of each cell line into sample buffer, and 60 μL of the diluted sample was subjected to 
electrophoresis on an 8% SDS-PAGE gel co-polymerized with 0.1% gelatine. Other details about 
gelatine zymography performance and the quantification of bands are reported in Phase 1. 
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RESULTS 
Gene expression 
The gene expression results for each cell line are summarised in Table 2. A higher MMP-9 mRNA 
expression was observed in OSW compared to the other cell lines; whereas MMP-2 was 
undetected in all cell lines. MT1-MMP and TIMP-1 expressions were observed in T-cell line (OSW), 
but no results were obtained in CLBL-1, CL-1 and GL-1. VEGF-A and VEGFR-2 transcripts were 
detected in all cell lines, but expression levels were higher in GL-1. Whereas B-cell leukaemia cell 
line (GL-1) presented higher TIMP-2 mRNA expression respect to CLBL-1, OSW and CL-1, which 
exhibited expression values close to 0. RECK was detected in the four cell lines, but T-cell line 
(OSW) presented a higher expression profiling. 
 
Table 2. MMP-9, MMP-2, MT1-MMP, TIMP-1, TIMP-2, VEGF-A, VEGF-164 and RECK mRNA 
expression in the four cell lines. 
CLBL-1 OSW CL-1 GL-1 
MMP-9 0,76 1128,35 0,05 0,03 
MMP-2 0,00 0,00 0,00 0,00 
MT1-MMP 0,04 4,11 0,01 0,00 
VEGF-A 4,87 1,42 3,11 9,42 
VEGF-164 7,99 3,18 4,68 20,53 
TIMP-1 0,72 2,38 0,00 0,72 
TIMP-2 0,00 0,82 0,00 28,54 
RECK 4,32 19,56 6,84 5,96 
Data are expressed as relative quantification values (mean ± SD) 
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Immunocytochemistry 
Immunocytochemical results are summarised in Table 3. The immunostaining scores for the target 
proteins were variable. CLBL-1 and OSW were positive immunostained for all markers (Fig. 2). 
 
Table 3. MMP-9, MMP-2, MT1-MMP, VEGF-A, VEGFR-2 and TIMP-2 protein expression in the four 
cell lines. 
CLBL-1 OSW CL-1 GL-1 
MMP-9 88 190 0 100 
MMP-2 44 0 0 90 
MT1-MMP 62 100 0 92 
VEGF-A 80 30 0 0 
VEGFR-2 68 90 92 0 
TIMP-2 46 198 100 198 
Data are expressed as immunostaining scores 
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Fig. 2. Immunostaining in four canine lymphohematopoietic malignancies cell lines. A) Intense MMP-2 
immunopositivity in CLBL-1. B) Moderate MT1-MMP immunopositivity in OSW. C) Intense MMP-9 
immunopositivity in OSW. D) Intense TIMP-2 immunopositivity in GL-1. E) Intense VEGF immunopositivity in 
CLBL-1. D) Intense VEGFR-2 immunopositivity in CL-1. (Immunohistochemistry, 400×). 
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Gelatin zymography 
Catalytic activities of both latent and mature form of MMP-2 and MMP-9 were undetected in all 
cell lines except for pro-MMP-9, which presented an identifiable band (Fig. 3). 
 
 
Fig. 3. Representative MMP zymography from canine Lymphohematopoietic malignancies cell lines, 
grown in the last 24 hours in medium with serum (as internal control) and serum-free. Lanes 1: positive 
control. Lane 2 and 3: CLBL-1 with serum and serum-free. Lanes 4 and 5: OSW with serum and serum-free. 
Lane 6 and 7: CL-1 with serum and serum-free. Lane 8 and 9: GL-1 with serum and serum-free. Lane 10: 
negative control. 
 
DISCUSSION 
Because the bone marrow and lymphatic organs are predominant sites of tumour accumulation in 
hematologic malignancies, it was initially believed that angiogenesis, in association with 
mechanisms of tumour invasion and growth, would not be as relevant in these disorders (‘‘liquid 
tumours’’) as it is in solid tumours. However many studies showed a relation between various 
hematologic malignancies and changes in the angiogenic profile (Letilovic et al. 2006). In this study 
different molecules in vitro were assessed, which are involved in the tumour invasion and 
angiogenesis to exclude the influence of microenvironment. The involvement of the MMPs and 
TIMPs in development of the metastatic phenotype in hematopoietic neoplasms both in vitro and 
in vivo is well established (Kossakowska et al., 1999; Stetler-Stevenson et al., 1997). The expression 
of MMP-9 using the sensitive zymogram technique didn’t show significative results for the four cell 
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lines in the present study. A considerable amount of the zymogram detection of pro-MMP-9 was 
only detected in the T-cells lymphoma (OSW), in association with its high mRNA and 
immunolabelling expression level. Biologically the role of this enzyme in normal lymphocyte is to 
permit the migration from the vascular compartment to sites of inflammation, contributing 
significantly to events associated with T-cell transmigration across the subendothelial basement 
membrane (Stetler-Stevenson et al., 1997). This process could be comparable to invasion of 
structures by lymphoma or leukemic cells, indicating that MMP-9 may play an important role 
correlated to the immunophenotype. Furthermore previous studies demonstrated that lymphoid 
cells in vitro, also using Matrigel (reconstituted basement membrane), may be induced to produce 
MMP-9 (Kossakowska et al., 1998). MMP-2 was not detected by RT-PCR and gelatin zymography, 
whereas the immunostaining expression was observed in B-cell lymphoma cell line (CLBL-1) and B-
cell leukaemia cell line (GL-1). This discrepancy between different methods, also observed in vivo, 
might be explained by the fact that MMP-2 protein activity is mainly regulated at the post-
transcriptional level (Brown et al., 1990). In different solid tumours it has been demonstrated the 
catalytic activity of MMP-2 with insignificant expression of MMP-2 mRNA (Caenazzo et al., 1998, 
Aresu et al., 2011). The same discrepancy was identified in CLBL-1 and GL-1 in regard to MMP-9 
results: lymphoid cells may produce MMPs upon interaction with basement membrane 
components, such as laminin, type IV collagen, or heparan sulfate proteoglycan, or in response to 
other tissue-specific interactions (eg, interaction with endothelial cells) that are not present under 
in vitro tissue culture conditions. Moreover the identification of the gelatinases mRNAs is, 
however, not synonymous with the presence of their enzymatic activity, as mRNA codes for the 
protein, which at first is present in the inactive latent form. The enzymatic activity of gelatinases is 
dependent on the activation of their latent forms (Kossakowska et al., 1998). High levels of TIMP-2 
RNA transcript and protein expression in B-cell leukaemia cell line (GL-1) were demonstrated, 
whereas TIMP-1 presented a similar trend with MMP-9, supporting the hypothesis that MMP-9 
and TIMP-1 may act in concert in canine T-cell lymphoma. Although the gelatinases may be 
expressed under different culture conditions, one would expect regulation of TIMP-1 and TIMP-2 
mirroring the one of MMP-9 and -2, due to the inhibitory action of the TIMPs. Therefore, the 
constitutive expression of the TIMPs without gelatinases suggests that they may have a growth 
factor activity (Kossakowska et al., 1991), similar to the demonstrated erytroid-potentiating 
activity (Stetler-Stevenson et al., 1997). 
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Interestingly MT1-MMP RNA transcript and protein reflected MMP-9 trend, with high values in 
OSW. Like MMP-9, MT1-MMP is known to have an important functional role in tumour invasion; it 
degrades ECM macromolecules, cytokines, and chemokines and stimulates the mobility and 
migration of neoplastic cells. MT1-MMP is also known to promote tumour angiogenesis, degrading 
the fibrin matrix that surrounds newly formed vessels (Egeblad et al., 2002). In regard to VEGF, the 
principal molecule and the isoform -164 were always expressed and presented similar trends with 
a higher mRNA expression level in GL-1 respect to the other cell lines. On the contrary in GL-1, 
VEGF-A protein expression was not observed. This could be explained by the fact that tumour 
growth in chronic lymphocytic leukaemia (CLL), as well as in other hematologic malignancies, is 
strongly influenced by angiogenesis, primarily through powerful cytokine interactions, both 
paracrine and autocrine. These interactions are found between at least three subsets of cells 
found in bone marrow: endothelial cells, nearby stromal cells and malignant CLL cells, which 
produce angiogenic factors such as VEGF, but only the first two could trigger the activation of 
these factors (Letilovic et al., 2006). In this study T-cell lines (OSW and CL-1) expressed higher 
levels of RECK mRNA than their B-cell counterparts (CLBL-1 and GL-1), as it was observed in vivo. It 
is hypothesised that RECK expression inversely correlates with that of MMPs due to its tumour-
suppressing activity (Noda et al., 2003). These results indicate that this simple direct relationship 
cannot hold true in the context of canine lymphomas. In humans, RECK down-regulation has been 
correlated with tumour progression and angiogenesis (Noda et al., 2003), but, in literature, no 
data have demonstrated the biologic behaviour of RECK in haematopoietic malignancies. In dogs, 
the mRNA expression levels of RECK in some tumour tissue samples were significantly lower than 
those in normal tissue samples (Takagi et al., 2005; Aresu et al., 2011). To my knowledge, this is 
the first study investigating MMPs and VEGF in canine hematopoietic cell lines by using transcript 
and protein analyses. The potential role of MMP-9, TIMP-1 and -2 in tumour invasion was 
confirmed. Moreover it was demonstrated that cancer cells in primary tumours have a strict 
interaction with their supportive microenvironment, which triggers the secretion of growth factors 
and proteases. This process allows amplifying activation the signals in the cascade that results in 
the establishment of an activated stroma that promotes malignant tumour growth. Further efforts 
should be directed towards new therapeutic approaches in the treatment of canine lymphoid 
malignancies focused on tumour microenvironment. 
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5.5. SECTION 5: Expression of Platelet-derived Growth Factor and its 
receptors in canine Lymphoma 
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BACKGROUND 
Platelet-derived growth factor (PDGF) and its receptors play a significant role in human 
hematopoietic malignancies. In Hodgkin’s lymphoma, it has been shown that the majority of Reed-
Sternberg cells express PDGFR-α and are dependent by PDGFR signalling, whereas normal B-cells 
or B-cells in NHL do not express PDGFR and do not rely on its signalling (Renne et al., 2005). 
Karabatsou et al. (2006) showed that primary central nervous system lymphomas express PDGFR-
α in the majority of investigated cases, whereas PDGF-A is expressed less frequently. A study on 
NHL showed PDGF-B level decrease after radiotherapy, with a possible predictive significance for 
response to treatment and recurrence (Ria et al., 2008), whereas Duşe et al. (2012) assessed 
PDGF-Rs protein expression in NHL. Interestingly, Ho et al. (2005) analysed the expression of PDGF 
in B-cell lineage, showing that abundant PDGF-A, rather than PDGF-B, was expressed in normal B 
cells. No difference was reported for the expression of PDGF-A and PDGF-B between patients with 
reactive lymphoid hyperplasia and B-cell chronic lymphocytic leukaemia (B-CLL) and B-cell 
lymphoma. Among the patients with B-CLL, the expression of PDGF-B was stronger than the 
expression of PDGF-A. They concluded that PDGF-A it is important in B cell differentiation and 
proliferation, considering its expression in all stages of B lymphocyte differentiation, whereas the 
expression of PDGF-B and PDGFR-β suggests that autocrine signalling of PDGF may be important in 
malignant transformation of B-CLL. At present time no data are available on the expression of 
PDGF and its receptors in canine hematopoietic malignancies. 
AIM  
To understand the possible correlation between the expression of PDGF-A and -B, in association 
with the expression of PDGFR-α and -β in canine lymphoma, their gene expression profiling will be 
defined in dogs with B-cell and T-cell lymphoma and with reactive hyperplasia, also focusing on 
possible prognostic and predictive role of these molecules. To combine and compare work in vitro 
and in vivo, PDGF-A, -B, PDGFR-α and -β mRNA expression was also assessed in four different 
canine lymphohaematopoietic tumour cell lines. 
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METHODS 
Cell lines 
Canine cell lines used in this study include: B-cell lymphoma cell line CLBL-1 (Rütgen et a., 2010),T-
cell lymphoma cell line OSW (Kisseberth et al., 2007), T-lymphoblastoid cell line CL-1 (Momoi et 
al., 1997) and B-cell leukaemia cell line GL-1 (Nakaichi et al., 1996) (Fig. 1). The cell culture 
conditions, sampling procedure and generated cDNA are described in Phase 3 – Section 4. 
Case Selection and Tissue Sampling 
Forty-two dogs underwent complete staging work-up, including physical examination, complete 
blood cell count, peripheral blood and bone marrow aspirate, thoracic radiography and abdominal 
ultrasound. Flow cytometric and cytological analysis of nodal or cutaneous fine-needle aspirate 
were described previously by Aresu et al. (2012). Furthermore histological examination and 
immunohistochemistry of nodal or cutaneous biopsy were assessed. Fresh tissue samples were 
also obtained and excised tumour lesions were immediately divided into aliquots and stored under 
diverse conditions for different analytical techniques. The dogs underwent surgery due to evident 
disease, and the explicit consent of the owner was obtained. Five control lymph nodes were 
obtained from pathogen-free adult dogs, with consent of owners. For histological examination and 
immunohistochemistry, the tissue was formalin-fixed and paraffin embedded. For RNA isolation, 
aliquots of approximately 100 mg were immersed in RNAlater® solution (Applied Biosystems, 
Foster City, CA) and stored at -20°C until use. Owners of dogs with lymphoma were offered to 
treat their animals with multidrug chemotherapy, consisting of doxorubicin, vincristine, 
cyclophosphamide, L-asparaginase and prednisone (Simon et al., 2006). In these dogs, fresh 
tissues were collected at three time points (at diagnosis, at the end of treatment and at relapse).  
Histological and immunohistochemical examination 
Samples were fixed in 4% buffered formalin, embedded in paraffin and cut at 3-μm sections. For 
histological examination, slides were stained with haematoxylin and eosin. An antibody panel for 
diagnosis of lymphoid neoplasms was evaluated by immunohistochemistry. The primary antibody 
incubation step was performed by an automated system for all antibodies (Ventana Medical 
Systems). A monoclonal Mouse Anti-Human CD3 (Clone F7.2.38, Dako, Atlanta, GA, USA, T cells; 
diluted 1 in 100), a monoclonal Mouse Anti-Human CD5 (Clone CD5/54/F6, Dako, T cells; diluted 1 
in 100),  a monoclonal Mouse Anti-Human CD79αcy (Clone HM57, Dako, all stages of B-cells; 
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diluted 1 in 100), a CD20 Epitope Specific Rabbit Antibody (RB-9013-P, Thermo Fisher Scientific Inc, 
Cheshire WA7 1TA, UK, mature B cells; diluted 1 in 800) were used. The Ventana ES automated 
immunohistochemistry system was used for the remainder of the staining procedure, including 
the incubation with a biotinylated anti-mouse secondary antibody, the diaminobenzidine 
substrate and a haematoxylin counterstain. Negative control slides were incubated with isotype-
matched immunoglobulin in parallel with each staining batch to confirm the specificity of the 
antibodies. The image analysis system included an Olympus BX51 microscope. Samples were 
classified based on WHO Classification of tumours of domestic animals (Valli et al., 2002). 
Quantitative real-time RT-PCR (qRT-PCR) 
Total RNA isolation and the formulation of final value are reported in Phase 1. First-strand cDNA 
was synthesised from 300 ng of total RNA using Superscript II (Invitrogen, Life Technologies, 
Carlsbad, CA) according to the manufacturer’s protocol. The generated cDNA was used as the 
template for quantitative real-time RT-PCR (qRT-PCR) in a LightCycler 480 Instrument (Roche 
Diagnostics, Basel, Switzerland) using standard PCR conditions. The qRT-PCR reactions consisted of 
5 µl of Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen, Life Technologies, Carlsbad, CA), 0,3 
µl of forward and reverse primers (10 µM) (the primer combination and final concentrations were 
optimized during assay setup) and 2,5 µl of diluted (1 to X) cDNA. The primers, shown in Table 1, 
were designed using Primer Express 2.0 (Applied Biosystem, Life Technologies, Carlsbad, CA). 
Calibration curves using a 7-fold serial dilution of a cDNA pool revealed PCR efficiencies near two 
and error values < 0.2. Canine transmembrane BAX inhibitor motif containing 4 (CGI-119) was 
chosen as reference gene for the absence of pathological state dependent differences in mRNA 
expression, as reported in Aricò et al. (2012).  
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Table 1: Primer sequences used for qRT-PCR amplification 
Genes Accession Numer Primer Sequence (5’-3’) 
PDGF-A NM_001190172.1 F: TTTGGAAGCAAGTCTGAGAGCC 
R: TGGCCTCCTCAATGCTTCTT 
PDGF-B NM_001003383.1 F: CCGAGTTGGACCTGAATTTG 
R: GTCTTGCACTCAGCGATCAT 
PDGFR-α AY525124.2 F: TTTCCCTTGGCGGCACAC 
R: GTCAGGCTTGGCCATCCG 
PDGFR-β NM_001003382.1 F: CACGCCTCTGACGAGATTTATG 
R: CTCGAGAAGCAGCACCAGCT 
 
Statistical analysis 
The statistical analysis of the gene expression results was performed using the Mann–Whitney 
test. A non-parametric Spearman correlation analysis was used to determine potential 
relationships among target genes. A non-parametric paired t test data (Wilcoxon signed rank test) 
was used to identify differences in gene expression between the samples collected in the three 
time points. GraphPad Prism 5 software (San Diego, California, USA) was used for all statistical 
evaluations. Statistical significance was set at p<0.05. Finally, Grubbs’ test was used to identify 
potential outliers. 
 
RESULTS 
Clinical results 
Thirty-three dogs with lymphoma and 9 with reactive hyperplasia were enrolled. In Table 2 
lymphoma subtypes are reported, based on cytological and flow cytometric, and histological and 
immunostochemical evaluation. At the end of treatment 4 dogs were in relapse (2 B-cell 
lymphomas and 2 T-cell lymphomas), whereas 9 dogs were in remission status (8 B-cell 
lymphomas and one T-cell lymphoma). Two out of 8 B-cell lymphoma in remission status 
experienced a relapse during the course of the study. 
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Table 2: Classification of lymphoid tumours 
Immunophenotype Subtype Number 
B-cell Diffuse Large B-cell Lymphoma (DLBCL) 19 
Marginal zone Lymphoma (MZL) 2 
Follicular Lymphoma (FL) 1 
T-cell Peripheral T-cell Lymphoma (PTCL) 5 
Cutaneous Lymphoma (CL) 3 
Lymphoblastic Lymphoma (LL) 3 
 
qRT-PCR 
The gene expression results for healthy control lymph nodes, reactive hyperplasia, B-cell and T-cell 
lymphomas and cell lines are summarised in Table 3. PDGF-A, PDGFR-α  and PDGFR-β mRNA 
levels in the healthy control lymph nodes were significantly higher than in lymphomas. A 
significantly higher PDGF-B mRNA expression was observed in T-cell lymphomas compared to B-
cell lymphomas. PDGF-B mRNA expression was significantly higher in cutaneous lymphomas 
respect to control lymph nodes. Interestingly PDGF-A, PDGFR-α and PDGFR-β mRNA levels in the 
healthy control lymph nodes, reactive hyperplasia and lymphoma in remission status (2,12 ± 0,91; 
2,9 ± 1,7; 1,81 ± 0,84 respectively) were similar; PDGF-B transcript amount was similar in reactive 
hyperplasias and lymphomas in remission status (1,83 ± 0,93), but lower in control lymph nodes. 
mRNA levels of all genes in cell lines were not quantifiable or very low, with the exception of 
PDGF-A and PDGFR-α mRNA expression in OSW and PDGF-A mRNA levels in GL-1. Comparing 
results at diagnosis and at the end of treatment in B-cell lymphomas, significant correlations were 
found between PDGFR-β and both PDGF isoforms at diagnosis, whereas in second time point 
between PDGF-A and PDGFR- α (Table 4). In Table 5 mRNA expression of all genes are reported in 
Diffuse Large b-cell Lymphoma (DLBCL) cases at relapse and after the end of treatment. Similar 
values at diagnosis and relapse were found whereas expression levels were higher but not 
significant at the end of chemotherapy. With a paired t test (Fig. 1) it was evident a significant 
expression trend (p < 0.05) of the 8 DLBCL cases of both PDGF isoforms and their receptors at the 
diagnosis and at the end of therapy, being higher mRNA levels at the second time point. 
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Table 3:  PDGF-A, PDGF-B, PDGFR-α and PDGFR-β mRNA expression in reactive hyperplasia, B-cell 
and T-cell lymphoma 
  PDGF-A PDGF-B PDGFR-α PDGFR-β 
B-cell lymphoma 0,84 ± 0,45 0,55 ± 0,36 0,78 ± 0,49 0,47 ± 0,34 
DLBCL 0,83 ± 0,41 0,56 ± 0,36 0,75 ± 0,46 0,44 ± 0,26 
nodal subtype 0,91 ± 0,76 0,52 ± 0,43 0,97 ± 0,77 0,67 ± 0,73 
T-cell lymphoma 0,79 ± 0,48 2,26 ± 1,96c 0,67 ± 0,36 0,68 ± 0,35 
PTCL 0,69 ± 0,34 2,13 ± 2,25 0,66 ± 0,48 0,52 ± 0,38 
CL 1,2 ± 0,6 3,48 ± 1,61
d 
0,9 ± 0,22 1,08 ± 0,11 
LL 0,56 ± 0,48 1,26 ± 1,63 0,47 ± 0,13 0,56 ± 0,14 
reative hyperplasia 1,95 ± 1,13 2,01 ± 1,36 2,29 ± 1,54 1,55 ± 0,85 
control 1,93 ± 0,73ab 0,91 ± 0,51 3,52 ± 0,71ab 1,35 ± 0,50ab 
CLBL-1  n.q. n.q. 5,01E-03 n.q. 
OSW 2,22 3,54E-03 3,46 1,05E-03 
CL-1 0,55 n.q. n.q. n.q. 
GL-1 1,54 n.q. 9,48E-03 3,26E-02 
Data are expressed as the mean ± standard error 
n.q. = not quantifiable 
a, b, c, d
 Significant differences between control lymph nodes and B-cell lymphomas, control lymph nodes and 
T-cell lymphoma,s B-cell lymphomas and T-cell lymphomas, cutaneous lymphomas and control lymph 
nodes, respectively (Mann–Whitney test, P < 0.05). 
 
Table 4:  Correlation between different genes in B-cell lymphoma 
  PDGFR-α PDGFR-β 
PDGF-A at end of treatment  
r=0,76 p<0,036 
at diagnosis  
r=0,58 p<0,0041 
PDGF-B / at diagnosis  
r=0,63 p<0,0014 
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Table 5:  PDGF-A, PDGF-B, PDGFR-α and PDGFR-β mRNA expression in two DLBCL cases in relapse 
after treatment  
PDGF-A 
 
diagnosis end of treatment relapse 
case 1 0,96 1,37 0,41 
case 2 0,96 1,37 0,73 
PDGF-B 
 
diagnosis end of treatment relapse 
case 1 0,55 3,50 0,51 
case 2 0,30 1,99 0,35 
PDGFR-α 
 
diagnosis end of treatment relapse 
case 1 0,44 2,23 0,49 
case 2 0,45 5,20 0,74 
PDGFR-β 
 
diagnosis end of treatment relapse 
case 1 0,20 1,57 0,23 
case 2 0,12 2,80 0,28 
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Fig. 1. Paired t test in two time point. Graphs showing the expression trend of PDGF and its receptors at 
the diagnosis (T0) and at the end of treatment (T1) in 8 cases of DLBCL. 
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DISCUSSION 
Several works have clarified the possible involvement of PDGF in human hematopoietic 
malignancies (Ho et al., 2005; Renne et al., 2005; Karabatsou et al., 2006; Ria et al., 2008), 
supporting the existence of an autocrine loop and the notion that it contributes to the 
uncontrollable growth of some malignant cells. Moreover, overexpression of PDGF and its 
receptors seems to be relevant in the pathogenesis of NHL (Karabatsou et al. 2006; Ria et al., 
2008; Duşe et al., 2012). Considering no data available at present about PDGF and PDGFRs 
expression in canine lymphoma, in the present study gene expression profiling of these molecules 
was assessed. The results obtained show that PDGF-A, PDGFR-α and PDGFR-β mRNA levels in the 
healthy control lymph nodes were significantly higher than in lymphoma-affected dogs. In human 
it is well documented that PDGFRs are poorly expressed in hematopoietic cells (Toffalini and 
Demoulin, 2010). Moreover PDGF-A, rather than PDGF-B, is expressed in normal B cell and there 
are no difference in the expression of PDGF-A and PDGF-B between patients with reactive 
lymphoid hyperplasia and patients with B-cell lymphoma (Ho et al., 2005).  Interestingly, in the 
present study, in T-cell lymphoma PDGF-B was significantly higher respect to B-cell counterpart: in 
particular cutaneous lymphoma subtype showed the most considerable mRNA expression levels. 
From the literature, cell lines corresponding to the advanced stage of a cutaneous T-cell 
lymphoma showed enhanced expression of PDGF; in addition, post-thymic T-cell malignancies, 
derived from activated T-cells, may produce and secrete growth factor, like PDGF (Su and Kadin, 
1989). Moreover an autocrine PDGF-BB/PDGF b-receptor loop was found to mediate survival of 
large granular lymphocyte leukaemia of both T- and NK-cell origin (Yang et al., 2010). The present 
data showed that canine T-cell lymphomas, in particular cutaneous subtype, may represent a new 
and important source of PDGF-B and that PDGF-B signalling could also be important in the 
pathogenesis of this neoplasia, contributing to its aggressive growth characteristics and different 
clinicopathologic behaviours. Considering the findings obtained in cell lines, PDGF-A and PDGFR-α 
expression in OSW (T-cell lymphoma cell line) and PDGF-A expression in GL-1 (B-cell leukaemia cell 
line) were the only highlighted. Therefore T-cell line showed the expression of a different isoform 
of PDGF (PDGF-A) and the interaction with its specific receptor. To explain this opposite trend in T-
cell lymphoma line respect to vivo model, it is important to note that different isoforms of PDGF 
give different cellular effects and responses, which is explained by their different interactions with 
α- and β-receptors (Heldin et al., 1998). Studies on PDGF in human hematopoietic cell lines are 
few and showed expression of PDGF-B and PDGFR-β in B-cell chronic lymphocytic leukaemia, 
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suggesting that autocrine signalling of PDGF may be important in the malignant transformation of 
this neoplasia (Ho et al., 2005), whereas PDGF-A was evident in pre-B acute lymphocytic 
leukaemia cell lines (Tsai et al., 1994). Comparing gene expression results at diagnosis and at the 
end of treatment in B-cell lymphoma, significant correlations were found between PDGFR-β and 
both PDGF isoforms A and B at diagnosis, whereas at the end of chemotherapy between PDGF-A 
and PDGFR-α. The two PDGF receptor types mediate similar, but not identical, cellular responses. 
After activation, both receptors stimulate cell proliferation and rearrangement of actin filaments. 
The β-receptor mediates a potent chemotactic response. Moreover, PDGF protects cells against 
conventional and programmed death (Heldin et al., 1998). Therefore it is possible that this 
different combination between PDGF isoforms and receptors leads to several cellular effects and 
responses which are unique during the disease. Further investigations are needed to deeply assess 
the ligand-induced activation of receptors and PDGF signalling in dogs. Interestingly a significant 
expression trend (p < 0.05) of all molecules investigated at the diagnosis and at the end of therapy 
was showed in DLBCL which experienced a remission status, with higher expression at the end of 
treatment. This finding confirms in B-cell lymphomas the low expression of PDGF and its receptors, 
whereas in remission status, in which lymph node tissue goes to a hyperplastic or atrophic 
condition, PDGF mRNA transcript amount increases. This biological behaviour can explain the 
similar gene expression profiling of all molecules in the healthy control lymph nodes, reactive 
hyperplasia and B-cell lymphoma in remission status, then the two DLBCL dogs in relapse at the 
end of treatment. In conclusion, PDGF-B is probably involved in the pathogenesis of canine T-cell 
lymphoma, in particular of cutaneous subtype, and the co-expression of PDGFs and PDGFRs in 
different time point during disease suggests a functional autocrine and/or paracrine loop of 
growth stimulation, which gives different cellular effects and responses. Further investigations are 
needed to deeply assess the role of PDGF and its receptors in canine lymphoma, especially 
considering protein analysis, which will be the further step. This evaluation is thought to identify 
the cellular type expressing these molecules (tumour cells and/or stromal cells), the intensity and 
the percentage of immunoassayed cells, to compare with gene expression findings. PDGF-B may 
represent new therapeutic target in canine T-cell lymphoma, but future studies should collect 
more clinical outcome data to further understand a potential prognostic role of this molecule. 
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6. GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES 
There is abundant evidence that crosstalk between tumour cells and their reactive stromal cells 
contributes to, or is even required for, tumour formation and progression. Tumour cells create a 
supportive microenvironment by secreting growth factors, proteases and their inhibitors, whose 
imbalance leads to the degradation of ECM, resulting in the release of growth factors, bound to 
the matrix, and of ECM molecular fragments. The secretion can act both in autocrine and 
paracrine manners to the stroma, inducing angiogenesis, invasion and proliferation of tumour 
cells. In addition to recruitment, proliferation and activation of stromal inflammatory cells and 
fibroblasts are activated, secreting further growth factors and proteases. This cycle permits to 
amplify these signals in the cascade resulting in the establishment of an activated stroma that 
promotes malignant tumour growth. Advantages to targeting the stroma include the fact that 
these cells are not genetically unstable as cancer cells, and are therefore less likely to develop drug 
resistance. Several exciting success stories have already been presented in the clinical targeting of 
tumour stroma (Mueller and Fusenig, 2004). It is important to note that “Normalization” of the 
stromal environment should be able to slow or even reverse tumour progression. “Normalize” 
microenvironment consists in a phenotypic reversion of a malignant and invasive to a non-invasive 
pre-malignant tumour phenotype. Blocking angiogenesis is considers one possible approach, in 
which the activated stromal compartment of malignant neoplasm is normalized, blood vessels 
acquire an intact basement membrane, and fibroblast activation is downregulated. As a 
consequence of the downregulation of MMPs or other proteases and reduced ECM turnover in the 
stroma, an intact basement-membrane zone is re-established and stromal collagen is reformed. As 
a result of this normalized stromal compartment, the malignant and invasive growth of tumour 
reverts to a pre-malignant dysplastic phenotype (Skobe et al., 1997). However, there are also 
some disappointments in targeting the stroma for cancer therapy in human, as reported in the 
results on clinical testing of MMP inhibitors: no efficacy in patients suffering from advanced stages 
of cancer; severe intolerable side effects and worsening the prognosis for the patient. To 
overcome these problems, in human oncology, the development of more specific inhibitors is now 
underway (Mueller and Fusenig, 2004). 
This research project has brought out several important results, which upgrade the background on 
the tumour progression and the role of microenvironment in veterinary oncology. These findings 
are: 
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- the involvement of MMP-2, MT1-MMP, MMP-9 in canine mammary tumours, with an 
emphasis on the stromal compartment;  
- the role of MMP-9 and VEGF-A in the progression and malignancy of canine cutaneous 
mast cell tumours; 
- MMP-9, MT1-MMP, TIMP-1 and VEGF influence in T-cell lymphomas and in dogs with a 
more advanced disease, highlighting the correlation with phenotype and grading; 
- the potential role of MT1-MMP and TIMP-2 in the pathogenesis of canine acute 
lymphoblastic leukaemia; 
- the influence of residual normal leukocytes in the expression of MMP-9, MT1-MMP, VEGF 
and TIMPs in chronic lymphocytic leukaemia ; 
- the observed discrepancy between in vivo and in vitro model in lymphoma and leukaemia 
to highlight the importance of microenvironment; 
- the possible interaction of PDGF-B in canine T-cell lymphoma, in particular in cutaneous 
subtypes, and the suggested functional autocrine and/or paracrine loop of growth 
stimulation confirmed by the co-expression of PDGFs and PDGFRs at different time point 
during disease. 
In the last years, the tumour vasculature has also become an attractive target for therapy in 
veterinary oncology. Therefore, the future in canine targeted therapy in mammary tumour, mast 
cell tumour, lymphoid leukaemia and lymphoma, will consider combination of drugs that target 
different aspects of the activated stroma with cytotoxic therapies that are directed against 
neoplastic cells. 
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